Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,700 | 2022-01-14 00:00:00 UTC | FDA approves expanded use of AbbVie's arthritis drug to treat eczema | ABBV | https://www.nasdaq.com/articles/fda-approves-expanded-use-of-abbvies-arthritis-drug-to-treat-eczema | null | null | Jan 14 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc's ABBV.N arthritis drug to treat eczema, a skin disease, the company said on Friday.
The approval of Rinvoq for the treatment of moderate to severe atopic dermatitis, or eczema, was for patients 12 years and older who do no... | Jan 14 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc's ABBV.N arthritis drug to treat eczema, a skin disease, the company said on Friday. The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer PFE.N, Eli Lilly LLY.N and AbbVie following th... | Jan 14 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc's ABBV.N arthritis drug to treat eczema, a skin disease, the company said on Friday. The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer PFE.N, Eli Lilly LLY.N and AbbVie following th... | Jan 14 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc's ABBV.N arthritis drug to treat eczema, a skin disease, the company said on Friday. The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer PFE.N, Eli Lilly LLY.N and AbbVie following th... | Jan 14 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of AbbVie Inc's ABBV.N arthritis drug to treat eczema, a skin disease, the company said on Friday. The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer PFE.N, Eli Lilly LLY.N and AbbVie following th... |
23,701 | 2022-01-14 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-4 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV — FREE Get the latest Zacks research report on MCD — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories (Symbol: ABT) $129.65 ... | Abbott Laboratories (Symbol: ABT) $129.65 $140.33 8.24% Sherwin-Williams Co (Symbol: SHW) $317.39 $342.06 7.77% RenaissanceRe Holdings Ltd. (Symbol: RNR) $169.68 $180.00 6.08% AbbVie Inc (Symbol: ABBV) $133.52 $141.42 5.91% McDonald's Corp (Symbol: MCD) $261.41 $275.29 5.31% The average 12-month analyst targets are onl... | Abbott Laboratories (Symbol: ABT) $129.65 $140.33 8.24% Sherwin-Williams Co (Symbol: SHW) $317.39 $342.06 7.77% RenaissanceRe Holdings Ltd. (Symbol: RNR) $169.68 $180.00 6.08% AbbVie Inc (Symbol: ABBV) $133.52 $141.42 5.91% McDonald's Corp (Symbol: MCD) $261.41 $275.29 5.31% The average 12-month analyst targets are onl... | Abbott Laboratories (Symbol: ABT) $129.65 $140.33 8.24% Sherwin-Williams Co (Symbol: SHW) $317.39 $342.06 7.77% RenaissanceRe Holdings Ltd. (Symbol: RNR) $169.68 $180.00 6.08% AbbVie Inc (Symbol: ABBV) $133.52 $141.42 5.91% McDonald's Corp (Symbol: MCD) $261.41 $275.29 5.31% The average 12-month analyst targets are onl... |
23,702 | 2022-01-13 00:00:00 UTC | Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds | ABBV | https://www.nasdaq.com/articles/pfizers-pfe-prevnar-20-plus-covid-vaccine-study-succeeds | null | null | Pfizer PFE announced positive top-line data from a phase III study evaluating the co-administration of its newly approved 20-valent pneumococcal conjugate vaccine, Prevnar-20 with it and partner BioNTech’s BNTX mRNA-based COVID-19 vaccine at the same time in adults 65 years of age or older.
The study also evaluated the... | Some other top-ranked stock large drug/biotech stocks are AbbVie ABBV and Regeneron REGN, both with a Zacks Rank of 2 (Buy). AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days. | Some other top-ranked stock large drug/biotech stocks are AbbVie ABBV and Regeneron REGN, both with a Zacks Rank of 2 (Buy). AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days. | Some other top-ranked stock large drug/biotech stocks are AbbVie ABBV and Regeneron REGN, both with a Zacks Rank of 2 (Buy). AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days. | Some other top-ranked stock large drug/biotech stocks are AbbVie ABBV and Regeneron REGN, both with a Zacks Rank of 2 (Buy). AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days. |
23,703 | 2022-01-13 00:00:00 UTC | 4 Top Dividend Payers of the S&P 500 | ABBV | https://www.nasdaq.com/articles/4-top-dividend-payers-of-the-sp-500 | null | null | While for some stocks in the S&P 500, it's their large dividend yields that make them attractive picks, I like to focus on companies with payout ratios below 50%. This shows a balance between fueling future business growth and returning cash to shareholders. Ultimately, these dividend growth stocks steadily outperform ... | Accounting for more than one-third of AbbVie's $14.4 billion in revenue during the third quarter of 2021, Humira's loss will weigh on overall sales and the company's valuation somewhat deflated in anticipation of this downside. AbbVie While Humira's 2023 loss of exclusivity (LOE) still looms over AbbVie (NYSE: ABBV), i... | AbbVie While Humira's 2023 loss of exclusivity (LOE) still looms over AbbVie (NYSE: ABBV), its stock has delivered total shareholder returns of nearly 400% since its spinoff from Abbott Laboratory on Jan. 1, 2013. Accounting for more than one-third of AbbVie's $14.4 billion in revenue during the third quarter of 2021, ... | With the largest dividend yield of this group at 4.2% and the highest dividend growth rate of 18% annualized over the last five years, AbbVie would be a great core holding for dividend growth investors over the long term. AbbVie may have the largest dividend yield, but all four stocks have similar dividend yield potent... | For example, AbbVie's two other immunology drugs, Rinvoq and Skyrizi, are expected to combine for $15 billion in sales by 2025, helping offset Humira's decline. With the largest dividend yield of this group at 4.2% and the highest dividend growth rate of 18% annualized over the last five years, AbbVie would be a great ... |
23,704 | 2022-01-12 00:00:00 UTC | Does Johnson & Johnson's Split Make Sense? | ABBV | https://www.nasdaq.com/articles/does-johnson-johnsons-split-make-sense | null | null | Johnson & Johnson (NYSE: JNJ) has been in business for well over a century. Many were blindsided when the company announced late last year that it would be splitting its medical device and pharmaceutical businesses from its consumer health business. The split is set to close sometime in the next two years. In this segm... | It wasn't exactly the same, but Abbott split off AbbVie which is it's pharma business from Abbott's lab which is their medical devices and that stuff. Rachel Warren owns AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Dec. 17, Fool.com contributors Rachel Warren, Jason Hall, Travis Hoium, T... | It wasn't exactly the same, but Abbott split off AbbVie which is it's pharma business from Abbott's lab which is their medical devices and that stuff. Rachel Warren owns AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Dec. 17, Fool.com contributors Rachel Warren, Jason Hall, Travis Hoium, T... | It wasn't exactly the same, but Abbott split off AbbVie which is it's pharma business from Abbott's lab which is their medical devices and that stuff. Rachel Warren owns AbbVie and Johnson & Johnson. Many were blindsided when the company announced late last year that it would be splitting its medical device and pharmac... | It wasn't exactly the same, but Abbott split off AbbVie which is it's pharma business from Abbott's lab which is their medical devices and that stuff. Rachel Warren owns AbbVie and Johnson & Johnson. In this segment of Backstage Pass, recorded on Dec. 17, Fool.com contributors Rachel Warren, Jason Hall, Travis Hoium, T... |
23,705 | 2022-01-12 00:00:00 UTC | Notable Wednesday Option Activity: EOG, EBIX, ABBV | ABBV | https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-eog-ebix-abbv | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in EOG Resources, Inc. (Symbol: EOG), where a total of 132,488 contracts have traded so far, representing approximately 13.2 million underlying shares. That amounts to about 329.5% of EOG's average daily trading vo... | Especially high volume was seen for the $120 strike call option expiring February 18, 2022, with 30,281 contracts trading so far today, representing approximately 3.0 million underlying shares of ABBV. Below is a chart showing EBIX's trailing twelve month trading history, with the $30 strike highlighted in orange: And ... | Below is a chart showing EBIX's trailing twelve month trading history, with the $30 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 180,273 contracts thus far today. Especially high volume was seen for the $120 strike call option expiring February 18, 2022, with 30,281 contra... | Especially high volume was seen for the $120 strike call option expiring February 18, 2022, with 30,281 contracts trading so far today, representing approximately 3.0 million underlying shares of ABBV. Below is a chart showing EBIX's trailing twelve month trading history, with the $30 strike highlighted in orange: And ... | Especially high volume was seen for the $120 strike call option expiring February 18, 2022, with 30,281 contracts trading so far today, representing approximately 3.0 million underlying shares of ABBV. Below is a chart showing EBIX's trailing twelve month trading history, with the $30 strike highlighted in orange: And ... |
23,706 | 2022-01-12 00:00:00 UTC | 2 Monster Stocks to Buy for 2022 That Are Practically Minting Money | ABBV | https://www.nasdaq.com/articles/2-monster-stocks-to-buy-for-2022-that-are-practically-minting-money | null | null | Since March 2009, growth stocks have enjoyed a very strong rally mainly due to the easy availability of cheap capital, thanks to an extremely low-interest rate environment. However, many growth stocks seem to have lost their sheen in the last few months of 2021 and early 2022. Stickier-than-expected inflation, a resurg... | Against this backdrop, AbbVie (NYSE: ABBV) and Meta Platforms (NASDAQ: FB) could prove to be attractive picks for retail investors. AbbVie Shares of leading biopharma company AbbVie rallied just over 26% in 2021, yet the company looks reasonably valued at 9.7 times forward earnings. Chances that AbbVie will continue mi... | Against this backdrop, AbbVie (NYSE: ABBV) and Meta Platforms (NASDAQ: FB) could prove to be attractive picks for retail investors. AbbVie Shares of leading biopharma company AbbVie rallied just over 26% in 2021, yet the company looks reasonably valued at 9.7 times forward earnings. Chances that AbbVie will continue mi... | AbbVie Shares of leading biopharma company AbbVie rallied just over 26% in 2021, yet the company looks reasonably valued at 9.7 times forward earnings. Against this backdrop, AbbVie (NYSE: ABBV) and Meta Platforms (NASDAQ: FB) could prove to be attractive picks for retail investors. Chances that AbbVie will continue mi... | Against this backdrop, AbbVie (NYSE: ABBV) and Meta Platforms (NASDAQ: FB) could prove to be attractive picks for retail investors. AbbVie Shares of leading biopharma company AbbVie rallied just over 26% in 2021, yet the company looks reasonably valued at 9.7 times forward earnings. Chances that AbbVie will continue mi... |
23,707 | 2022-01-12 00:00:00 UTC | Here's A Better Pharmaceutical Pick Over Merck Stock | ABBV | https://www.nasdaq.com/articles/heres-a-better-pharmaceutical-pick-over-merck-stock | null | null | We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trailing revenues, compared to 3.6x for MRK stock. That said, this gap in valuation ... | We compare a slew of factors such as historical revenue growth, returns, and valuation multiple in an interactive dashboard analysis Merck vs Bristol Myers Squibb: Which Stock Is A Better Bet? Note that Bristol Myers Squibb margins over the last twelve month period were negatively impacted due to a one-time in-process ... | We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trailing revenues, compared to 3.6x for MRK stock. Bristol Myers Squibb’s Revenue Gr... | We think that Bristol Myers Squibb stock (NYSE: BMY) currently is a better pick compared to its industry peer, Merck stock (NYSE: MRK), given its better growth prospects and comparatively lower valuation, with its stock trading at 3.0x trailing revenues, compared to 3.6x for MRK stock. Bristol Myers Squibb’s Revenue Gr... | Our Merck Revenue and Bristol Myers Squibb Revenue dashboards provides more insight on the companies’ revenues. The Net of It All We see that the revenue growth over the recent quarters has been stronger for Merck and it is more profitable compared to Bristol Myers Squibb. The table below summarizes our revenue and ret... |
23,708 | 2022-01-11 00:00:00 UTC | AbbVie To Present At J.P. Morgan Healthcare Conference; Webcast At 3:45 PM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-j.p.-morgan-healthcare-conference-webcast-at-3%3A45-pm-et | null | null | (RTTNews) - AbbVie (ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference.
The event is scheduled to begin at 3:45 PM ET on January 11, 2022.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the ... | (RTTNews) - AbbVie (ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect tho... | (RTTNews) - AbbVie (ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect tho... | (RTTNews) - AbbVie (ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect tho... | (RTTNews) - AbbVie (ABBV) will participate in the 40th Annual J.P. Morgan Healthcare Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect tho... |
23,709 | 2022-01-11 00:00:00 UTC | AbbVie Confirms Outlook Of Over $15 Bln In Combined Risk-Adj. Sales For Rinvoq, Skyrizi In 2025 | ABBV | https://www.nasdaq.com/articles/abbvie-confirms-outlook-of-over-%2415-bln-in-combined-risk-adj.-sales-for-rinvoq-skyrizi-in | null | null | (RTTNews) - AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025.
AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi.
The new Rinvoq sa... | (RTTNews) - AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. The new Rinvoq sa... | AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. (RTTNews) - AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025. The new Rinvoq sa... | AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. (RTTNews) - AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025. The new Rinvoq sa... | (RTTNews) - AbbVie (ABBV) confirmed prior revenue guidance of more than $15 billion in combined Rinvoq or upadacitinib and Skyrizi or risankizumab risk-adjusted sales in 2025. AbbVie now expects 2025 risk-adjusted sales of greater than $7.5 billion for Rinvoq and greater than $7.5 billion for Skyrizi. The new Rinvoq sa... |
23,710 | 2022-01-10 00:00:00 UTC | Noteworthy ETF Inflows: VLUE, MU, ABBV, C | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vlue-mu-abbv-c | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI USA Value Factor ETF (Symbol: VLUE) where we have detected an approximate $242.6 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 146,95... | Among the largest underlying components of VLUE, in trading today Micron Technology Inc. (Symbol: MU) is off about 2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Citigroup Inc (Symbol: C) is lower by about 0.6%. For a complete list of holdings, visit the VLUE Holdings page » The chart below shows the one year pric... | Among the largest underlying components of VLUE, in trading today Micron Technology Inc. (Symbol: MU) is off about 2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Citigroup Inc (Symbol: C) is lower by about 0.6%. For a complete list of holdings, visit the VLUE Holdings page » The chart below shows the one year pric... | Among the largest underlying components of VLUE, in trading today Micron Technology Inc. (Symbol: MU) is off about 2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Citigroup Inc (Symbol: C) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of VLUE, in trading today Micron Technology Inc. (Symbol: MU) is off about 2%, AbbVie Inc (Symbol: ABBV) is up about 0.8%, and Citigroup Inc (Symbol: C) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
23,711 | 2022-01-09 00:00:00 UTC | 3 No-Brainer Big Pharma Stocks to Buy in 2022 | ABBV | https://www.nasdaq.com/articles/3-no-brainer-big-pharma-stocks-to-buy-in-2022 | null | null | Going big can sometimes pay off. That's especially the case when you invest in the stocks of top large drugmakers.
We asked three Motley Fool contributors to identify the big pharma stocks that they think are no-brainer picks to buy in 2022. Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Phar... | As he said during the company's third-quarter earnings conference call: "[Skyrizi and Rinvoq] are either approved, under regulatory review, or in late-stage development across all of Humira's major indications, and we remain confident that they will both be significant contributors to AbbVie's long-term growth." Here's... | Keith Speights owns AbbVie, Pfizer, and Vertex Pharmaceuticals. Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). This company isn't a one-trick pony Prosper Junior Bakiny (AbbVie): The bears have been predicting AbbVie's doom since the company lost patent protect... | This company isn't a one-trick pony Prosper Junior Bakiny (AbbVie): The bears have been predicting AbbVie's doom since the company lost patent protection for its blockbuster rheumatoid arthritis drug, Humira, back in 2018. Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). This company isn't a one-trick pony Prosper Junior Bakiny (AbbVie): The bears have bee... |
23,712 | 2022-01-08 00:00:00 UTC | Just Four Days Till AbbVie Inc. (NYSE:ABBV) Will Be Trading Ex-Dividend | ABBV | https://www.nasdaq.com/articles/just-four-days-till-abbvie-inc.-nyse%3Aabbv-will-be-trading-ex-dividend | null | null | AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date is one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend. It is important to be aware of the ex-dividend date because any trade on t... | Based on the last year's worth of payments, AbbVie stock has a trailing yield of around 4.2% on the current share price of $134.88. AbbVie Inc. (NYSE:ABBV) stock is about to trade ex-dividend in four days. Meaning, you will need to purchase AbbVie's shares before the 13th of January to receive the dividend, which will ... | It's disappointing to see that the dividend was not covered by profits, but cash is more important from a dividend sustainability perspective, and AbbVie fortunately did generate enough cash to fund its dividend. NYSE:ABBV Historic Dividend January 8th 2022 Have Earnings And Dividends Been Growing? AbbVie Inc. (NYSE:AB... | If you buy this business for its dividend, you should have an idea of whether AbbVie's dividend is reliable and sustainable. It's disappointing to see that the dividend was not covered by profits, but cash is more important from a dividend sustainability perspective, and AbbVie fortunately did generate enough cash to f... | It's disappointing to see that the dividend was not covered by profits, but cash is more important from a dividend sustainability perspective, and AbbVie fortunately did generate enough cash to fund its dividend. AbbVie has been steadily growing its earnings per share, and it is paying out just 42% of its cash flow but... |
23,713 | 2022-01-07 00:00:00 UTC | AbbVie Submits Applications For Upadacitinib In Non-Radiographic Axial Spondyloarthritis To FDA | ABBV | https://www.nasdaq.com/articles/abbvie-submits-applications-for-upadacitinib-in-non-radiographic-axial-spondyloarthritis | null | null | (RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective sig... | (RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective sig... | (RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective sig... | (RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective sig... | (RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective sig... |
23,714 | 2022-01-06 00:00:00 UTC | Abbvie Inc Shares Near 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-near-52-week-high-market-mover-1 | null | null | Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $138.15, giving the company a market cap of $240B. The stock is currently up 0.3% year-to-date, up 33.7% over the past 12 months, and up 168.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.... | Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $138.15, giving the company a market cap of $240B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $138.15, giving the company a market cap of $240B. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 12.1% higher than the 20-day average. | Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $138.15, giving the company a market cap of $240B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $138.15, giving the company a market cap of $240B. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,715 | 2022-01-06 00:00:00 UTC | 4 EV Charging Stocks to Buy Ahead of Biden’s National Network | ABBV | https://www.nasdaq.com/articles/4-ev-charging-stocks-to-buy-ahead-of-bidens-national-network | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If you’ve been thinking about electric vehicle charging stocks, you’re not alone.
The electric vehicle space has been a hot one on Wall Street for a couple of years now. And now the White House is putting renewed emphasis on the sector with its recent infra... | According to Insider Monkey, the cleantech company has contracts with the U.S. Marines Corps and NASA, and commercial contracts with AbbVie (NYSE:ABBV) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). The $1 trillion package championed by President Joe Biden includes $7.5 billion that is earmarked for a national network of 50... | According to Insider Monkey, the cleantech company has contracts with the U.S. Marines Corps and NASA, and commercial contracts with AbbVie (NYSE:ABBV) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). Here are four to consider: ChargePoint Holdings (NYSE:CHPT) EVgo (NASDAQ:EVGO) Beam Global (NASDAQ:BEEM) Volta Charging (NYSE:... | According to Insider Monkey, the cleantech company has contracts with the U.S. Marines Corps and NASA, and commercial contracts with AbbVie (NYSE:ABBV) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). Here are four to consider: ChargePoint Holdings (NYSE:CHPT) EVgo (NASDAQ:EVGO) Beam Global (NASDAQ:BEEM) Volta Charging (NYSE:... | According to Insider Monkey, the cleantech company has contracts with the U.S. Marines Corps and NASA, and commercial contracts with AbbVie (NYSE:ABBV) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). EV Charging Stocks to Buy: ChargePoint Holdings (CHPT) CHPT) charging station." EVgo (EVGO) Source: Sundry Photography / Shutt... |
23,716 | 2022-01-05 00:00:00 UTC | July 15th Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/july-15th-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the July 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 191 days until expiration the newly trading contracts represent a possible opportunity for sellers of put... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $90.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $145.00 strike price has a current bid of $4.30. Below is a chart showing ABBV... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new July 15th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Consideri... |
23,717 | 2022-01-05 00:00:00 UTC | AbbVie Gets Breakthrough Therapy Designation for Lung Cancer Treatment | ABBV | https://www.nasdaq.com/articles/abbvie-gets-breakthrough-therapy-designation-for-lung-cancer-treatment | null | null | The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to biopharmaceutical company AbbVie, Inc.’s (ABBV) investigational telisotuzumab vedotin (Teliso-V) to treat patients suffering from advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small... | The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to biopharmaceutical company AbbVie, Inc.’s (ABBV) investigational telisotuzumab vedotin (Teliso-V) to treat patients suffering from advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small... | The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to biopharmaceutical company AbbVie, Inc.’s (ABBV) investigational telisotuzumab vedotin (Teliso-V) to treat patients suffering from advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small... | The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to biopharmaceutical company AbbVie, Inc.’s (ABBV) investigational telisotuzumab vedotin (Teliso-V) to treat patients suffering from advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small... | The Vice-President and Global Head of Oncology Clinical Development at AbbVie, Mohamed Zaki, said, “Patients with non-small cell lung cancer have a high unmet need and Teliso-V has the potential to provide them with an additional treatment option to manage their disease.” Teliso-V’s BTD designation is based on data fro... |
23,718 | 2022-01-04 00:00:00 UTC | AbbVie: Teliso-V Gets Breakthrough Therapy Designation | ABBV | https://www.nasdaq.com/articles/abbvie%3A-teliso-v-gets-breakthrough-therapy-designation | null | null | (RTTNews) - AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose di... | (RTTNews) - AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose di... | (RTTNews) - AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose di... | (RTTNews) - AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose di... | (RTTNews) - AbbVie (ABBV) announced FDA granted Breakthrough Therapy Designation to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with high levels of c-Met overexpression whose di... |
23,719 | 2022-01-04 00:00:00 UTC | Abbvie Inc Shares Approach 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-approach-52-week-high-market-mover-1 | null | null | Abbvie Inc (ABBV) shares closed today at 1.0% below its 52 week high of $136.83, giving the company a market cap of $239B. The stock is currently up 0.0% year-to-date, up 32.4% over the past 12 months, and up 173.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.... | Abbvie Inc (ABBV) shares closed today at 1.0% below its 52 week high of $136.83, giving the company a market cap of $239B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 1.0% below its 52 week high of $136.83, giving the company a market cap of $239B. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.1%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 1.0% below its 52 week high of $136.83, giving the company a market cap of $239B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 1.0% below its 52 week high of $136.83, giving the company a market cap of $239B. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.1%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,720 | 2022-01-04 00:00:00 UTC | This Big Pharma Stock Is Enriching Shareholders With Its Dividend. But Is It a Buy? | ABBV | https://www.nasdaq.com/articles/this-big-pharma-stock-is-enriching-shareholders-with-its-dividend.-but-is-it-a-buy | null | null | Two signs that a company is focused on creating significant value for its shareholders are when the company boosts its dividend and when it repurchases its shares at attractive valuations.
Pharma stock Bristol Myers Squibb (NYSE: BMY) recently announced a 10.2% hike in its quarterly dividend to $0.54 per share. And if ... | While Bristol Myers Squibb's debt-to-EBITDA ratio is weaker than Johnson & Johnson's of 1.5, it's stronger than AbbVie's of 3.2. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Bristol Myers Squibb, and Johnson & Johnson. Bristol Myers Squibb is positioned to hit the low end of... | See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Bristol Myers Squibb, and Johnson & Johnson. While Bristol Myers Squibb's debt-to-EBITDA ratio is weaker than Johnson & Johnson's of 1.5, it's stronger than AbbVie's of 3.2. Let's dig into Bristol Myers Squibb's cash flow capabili... | While Bristol Myers Squibb's debt-to-EBITDA ratio is weaker than Johnson & Johnson's of 1.5, it's stronger than AbbVie's of 3.2. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Bristol Myers Squibb, and Johnson & Johnson. Bristol Myers Squibb is a cash flow machine At the heart... | While Bristol Myers Squibb's debt-to-EBITDA ratio is weaker than Johnson & Johnson's of 1.5, it's stronger than AbbVie's of 3.2. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Bristol Myers Squibb, and Johnson & Johnson. Let's dig into Bristol Myers Squibb's cash flow capabili... |
23,721 | 2022-01-03 00:00:00 UTC | My Top 5 Dividend Stocks to Buy for 2022 | ABBV | https://www.nasdaq.com/articles/my-top-5-dividend-stocks-to-buy-for-2022 | null | null | A strong dividend portfolio can be a powerful wealth-building tool, delivering gains from rising share prices and passive income. Many stocks pay dividends, but I would argue that blue chip companies are the winning strategy for long-term investors. In other words, let high-quality stocks do all the heavy lifting for y... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) is one of the world's largest drug companies, behind well-known products like Botox and Humira, the world's top-selling prescription drug. ABBV Cash Dividend Payout Ratio data by YCharts Usually dividend stocks either pay a small starting yield and grow rapidly, or pay ... | ABBV Cash Dividend Payout Ratio data by YCharts Usually dividend stocks either pay a small starting yield and grow rapidly, or pay a high starting yield and grow modestly. AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) is one of the world's largest drug companies, behind well-known products like Botox and Humira, th... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) is one of the world's largest drug companies, behind well-known products like Botox and Humira, the world's top-selling prescription drug. ABBV Cash Dividend Payout Ratio data by YCharts Usually dividend stocks either pay a small starting yield and grow rapidly, or pay ... | AbbVie Pharmaceutical company AbbVie (NYSE: ABBV) is one of the world's largest drug companies, behind well-known products like Botox and Humira, the world's top-selling prescription drug. ABBV Cash Dividend Payout Ratio data by YCharts Usually dividend stocks either pay a small starting yield and grow rapidly, or pay ... |
23,722 | 2022-01-03 00:00:00 UTC | What Does This Regulatory News Mean for Bristol Myers Squibb's Shareholders? | ABBV | https://www.nasdaq.com/articles/what-does-this-regulatory-news-mean-for-bristol-myers-squibbs-shareholders | null | null | In late November, the U.S. Food and Drug Administration (FDA) announced that it accepted Bristol Myers Squibb's (NYSE: BMY) New Drug Application for deucravacitinib as a treatment for patients with moderate-to-severe psoriasis.
With the FDA targeting a decision on deucravacitinib in September 2022, let's dive into the ... | Because the market is flush with psoriasis treatments like Johnson & Johnson's (NYSE: JNJ) Tremfya, AbbVie's (NYSE: ABBV) Humira, and Amgen's Otezla, I expect that deucravacitinib will achieve a 6% patient share. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Amgen, Bristol My... | Because the market is flush with psoriasis treatments like Johnson & Johnson's (NYSE: JNJ) Tremfya, AbbVie's (NYSE: ABBV) Humira, and Amgen's Otezla, I expect that deucravacitinib will achieve a 6% patient share. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Amgen, Bristol My... | Because the market is flush with psoriasis treatments like Johnson & Johnson's (NYSE: JNJ) Tremfya, AbbVie's (NYSE: ABBV) Humira, and Amgen's Otezla, I expect that deucravacitinib will achieve a 6% patient share. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Amgen, Bristol My... | Because the market is flush with psoriasis treatments like Johnson & Johnson's (NYSE: JNJ) Tremfya, AbbVie's (NYSE: ABBV) Humira, and Amgen's Otezla, I expect that deucravacitinib will achieve a 6% patient share. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Amgen, Bristol My... |
23,723 | 2022-01-02 00:00:00 UTC | Could This FDA Approval Create a Blockbuster Drug for AbbVie? | ABBV | https://www.nasdaq.com/articles/could-this-fda-approval-create-a-blockbuster-drug-for-abbvie | null | null | On Dec. 14, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Rinvoq as a treatment for adult patients with psoriatic arthritis who failed at least one other tumor necrosis factor (TNF) inhibitor. A new indication is always a positive sign for a drugmaker, especially one like AbbVie that is see... | On Dec. 14, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Rinvoq as a treatment for adult patients with psoriatic arthritis who failed at least one other tumor necrosis factor (TNF) inhibitor. Let's dig into the phase 3 clinical trial results of Rinvoq in treating psoriatic arthritis to ans... | On Dec. 14, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Rinvoq as a treatment for adult patients with psoriatic arthritis who failed at least one other tumor necrosis factor (TNF) inhibitor. Based on guidelines from the American College of Rheumatology, the first line of treatment for pso... | On Dec. 14, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Rinvoq as a treatment for adult patients with psoriatic arthritis who failed at least one other tumor necrosis factor (TNF) inhibitor. Let's dig into the phase 3 clinical trial results of Rinvoq in treating psoriatic arthritis to ans... | But will this create a blockbuster indication for the pharma stock AbbVie? On Dec. 14, the U.S. Food and Drug Administration (FDA) approved AbbVie's (NYSE: ABBV) Rinvoq as a treatment for adult patients with psoriatic arthritis who failed at least one other tumor necrosis factor (TNF) inhibitor. A new indication is alw... |
23,724 | 2022-01-02 00:00:00 UTC | 22 Top Dividend Stocks to Buy and Hold in 2022 | ABBV | https://www.nasdaq.com/articles/22-top-dividend-stocks-to-buy-and-hold-in-2022 | null | null | I don't know how the stock market will perform in the new year. Wall Street analysts don't know, either. Any predictions are really only guesses.
There's no guesswork required, though, to expect that many stocks will continue to pay solid dividends regardless of what happens with the overall market. These are the kinds... | Abbott Labs (NYSE: ABT) $248 billion 1.33% AbbVie (NYSE: ABBV) $238 billion 4.20% Air Products & Chemicals (NYSE: APD) $68 billion 1.97% Bristol Myers Squibb (NYSE: BMY) $138 billion 3.47% Brookfield Industrial Corporation (NYSE: BIPC) $5 billion 2.97% Brookfield Industrial Partners (NYSE: BIP) $18 billion 3.40% Brookf... | Abbott Labs (NYSE: ABT) $248 billion 1.33% AbbVie (NYSE: ABBV) $238 billion 4.20% Air Products & Chemicals (NYSE: APD) $68 billion 1.97% Bristol Myers Squibb (NYSE: BMY) $138 billion 3.47% Brookfield Industrial Corporation (NYSE: BIPC) $5 billion 2.97% Brookfield Industrial Partners (NYSE: BIP) $18 billion 3.40% Brookf... | Abbott Labs (NYSE: ABT) $248 billion 1.33% AbbVie (NYSE: ABBV) $238 billion 4.20% Air Products & Chemicals (NYSE: APD) $68 billion 1.97% Bristol Myers Squibb (NYSE: BMY) $138 billion 3.47% Brookfield Industrial Corporation (NYSE: BIPC) $5 billion 2.97% Brookfield Industrial Partners (NYSE: BIP) $18 billion 3.40% Brookf... | See the 10 stocks *Stock Advisor returns as of December 16, 2021 Keith Speights owns AbbVie, Air Products & Chemicals, Bristol Myers Squibb, Brookfield Infrastructure Corporation, Brookfield Infrastructure Partners, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., Devon Energy, Enterprise Prod... |
23,725 | 2021-12-31 00:00:00 UTC | AbbVie Reaches Analyst Target Price | ABBV | https://www.nasdaq.com/articles/abbvie-reaches-analyst-target-price | null | null | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $135.54, changing hands for $135.93/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $135.54, changing hands for $135.93/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contribution... | In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $135.54, changing hands for $135.93/share. But the whole reason to look at the average ABBV price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contribution... | There are 13 different analyst targets within the Zacks coverage universe contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. And so with ABBV crossing above that average target price of $135.54/share, investors in ABBV have been given a good signal to spend fresh time as... | There are 13 different analyst targets within the Zacks coverage universe contributing to that average for AbbVie Inc, but the average is just that — a mathematical average. In recent trading, shares of AbbVie Inc (Symbol: ABBV) have crossed above the average analyst 12-month target price of $135.54, changing hands for... |
23,726 | 2021-12-30 00:00:00 UTC | Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock | ABBV | https://www.nasdaq.com/articles/best-stocks-for-2022%3A-why-abbvie-looks-like-high-dividend-growth-stock | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2021 contest. Bob Ciura’s pick for the contest is AbbVie Inc. (NYSE:ABBV) stock.
Source: InvestorPlace
The stock market has something to offer every investor. There are stocks with hi... | Growth Catalysts for ABBV Stock Overall, AbbVie has invested significant resources in its research and development (R&D) platform to restock its pipeline. The result of this investment is that AbbVie has multiple growth opportunities to replace Humira, particularly in the therapeutic areas of immunology, hematology and... | At the midpoint of guidance, AbbVie’s adjusted EPS is expected to rise by roughly 20% this year — making 2021 another year of strong growth for ABBV stock. This is a unique find in the stock market, and it means AbbVie could generate superior returns through dividends and capital gains. Bob Ciura’s pick for the contest... | Final Thoughts on ABBV Stock Putting it all together, AbbVie is a rare example of a growth company with a reasonable valuation and a high dividend yield. The post Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock appeared first on InvestorPlace. Bob Ciura’s pick for the contest is AbbVie Inc. (NYSE... | One such company that comes to mind that offers this type of opportunity is AbbVie Inc. (NYSE:ABBV) and ABBV stock. At the midpoint of guidance, AbbVie’s adjusted EPS is expected to rise by roughly 20% this year — making 2021 another year of strong growth for ABBV stock. Furthermore, AbbVie is a dividend growth company... |
23,727 | 2021-12-30 00:00:00 UTC | 5 Dividend Stocks To Watch In 2022 | ABBV | https://www.nasdaq.com/articles/5-dividend-stocks-to-watch-in-2022 | null | null | Are These The Best Dividend Stocks To Buy In 2022?
Despite the recent volatility in the stock market, 2021 is ending the year with strong gains. The S&P 500 is up 29%, which is significantly higher than its historical average. With the rising threats of the Omicron variant and inflation fears, it’s not difficult to ima... | Top Dividend Stocks To Watch In 2022 Pfizer Inc. (NYSE: PFE) Brookfield Renewable Partners LP (NYSE: BEP) Caterpillar Inc. (NYSE: CAT) Abbott Laboratories (NYSE: ABT) Abbvie Inc. (NYSE: ABBV) Pfizer Pfizer has been stealing the show since its Comirnaty coronavirus vaccine was approved in most major countries. Abbvie Si... | Top Dividend Stocks To Watch In 2022 Pfizer Inc. (NYSE: PFE) Brookfield Renewable Partners LP (NYSE: BEP) Caterpillar Inc. (NYSE: CAT) Abbott Laboratories (NYSE: ABT) Abbvie Inc. (NYSE: ABBV) Pfizer Pfizer has been stealing the show since its Comirnaty coronavirus vaccine was approved in most major countries. Abbvie Si... | Top Dividend Stocks To Watch In 2022 Pfizer Inc. (NYSE: PFE) Brookfield Renewable Partners LP (NYSE: BEP) Caterpillar Inc. (NYSE: CAT) Abbott Laboratories (NYSE: ABT) Abbvie Inc. (NYSE: ABBV) Pfizer Pfizer has been stealing the show since its Comirnaty coronavirus vaccine was approved in most major countries. Abbvie Si... | For investors looking for best dividend stocks in 2022, look no further than AbbVie. Top Dividend Stocks To Watch In 2022 Pfizer Inc. (NYSE: PFE) Brookfield Renewable Partners LP (NYSE: BEP) Caterpillar Inc. (NYSE: CAT) Abbott Laboratories (NYSE: ABT) Abbvie Inc. (NYSE: ABBV) Pfizer Pfizer has been stealing the show si... |
23,728 | 2021-12-30 00:00:00 UTC | Teva fueled opioid addiction in New York, jury finds | ABBV | https://www.nasdaq.com/articles/teva-fueled-opioid-addiction-in-new-york-jury-finds | null | null | By Brendan Pierson
NEW YORK, Dec 30 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA fueled opioid addiction in New York state, a jury found on Thursday, a setback for a company still facing thousands of other opioid-related lawsuits around the United States.
The verdict, which followed a nearly six-month New Yor... | Other defendants in the case settled before or during trial - major pharmacies, distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, and drugmakers Johnson & Johnson, Endo International Plc and AbbVie Inc. AbbVie's settlement, for $200 million, came at the very end of the trial, on the day of clo... | Other defendants in the case settled before or during trial - major pharmacies, distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, and drugmakers Johnson & Johnson, Endo International Plc and AbbVie Inc. AbbVie's settlement, for $200 million, came at the very end of the trial, on the day of clo... | Other defendants in the case settled before or during trial - major pharmacies, distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, and drugmakers Johnson & Johnson, Endo International Plc and AbbVie Inc. AbbVie's settlement, for $200 million, came at the very end of the trial, on the day of clo... | Other defendants in the case settled before or during trial - major pharmacies, distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health Inc, and drugmakers Johnson & Johnson, Endo International Plc and AbbVie Inc. AbbVie's settlement, for $200 million, came at the very end of the trial, on the day of clo... |
23,729 | 2021-12-30 00:00:00 UTC | Abbvie Inc Shares Near 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-near-52-week-high-market-mover-0 | null | null | Abbvie Inc (ABBV) shares closed today at 0.4% below its 52 week high of $135.87, giving the company a market cap of $239B. The stock is currently up 32.4% year-to-date, up 35.5% over the past 12 months, and up 171.5% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2... | Abbvie Inc (ABBV) shares closed today at 0.4% below its 52 week high of $135.87, giving the company a market cap of $239B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.4% below its 52 week high of $135.87, giving the company a market cap of $239B. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.4% below its 52 week high of $135.87, giving the company a market cap of $239B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.4% below its 52 week high of $135.87, giving the company a market cap of $239B. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.1%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,730 | 2021-12-30 00:00:00 UTC | Notable Thursday Option Activity: BIIB, ABBV, GPN | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-biib-abbv-gpn | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 29,370 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 191% of BIIB's average daily trading volume over the pa... | Especially high volume was seen for the $140 strike call option expiring February 18, 2022, with 31,661 contracts trading so far today, representing approximately 3.2 million underlying shares of ABBV. Below is a chart showing BIIB's trailing twelve month trading history, with the $235 strike highlighted in orange: Abb... | Below is a chart showing BIIB's trailing twelve month trading history, with the $235 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 92,132 contracts thus far today. That number of contracts represents approximately 9.2 million underlying shares, working out to a sizeable 132.2% ... | That number of contracts represents approximately 9.2 million underlying shares, working out to a sizeable 132.2% of ABBV's average daily trading volume over the past month, of 7.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $235 strike highlighted in orange: AbbVie I... | Below is a chart showing GPN's trailing twelve month trading history, with the $150 strike highlighted in orange: For the various different available expirations for BIIB options, ABBV options, or GPN options, visit StockOptionsChannel.com. Below is a chart showing BIIB's trailing twelve month trading history, with the... |
23,731 | 2021-12-30 00:00:00 UTC | 3 Dividend Kings That Are Yielding More Than 3% | ABBV | https://www.nasdaq.com/articles/3-dividend-kings-that-are-yielding-more-than-3 | null | null | Dividend Kings are among the safest dividend growth stocks you can invest in. These are stocks of companies that have track records of increasing dividend payments for at least 50 years in a row. To break that streak would require something massive to happen, which is why it's generally a safe assumption that not only ... | Three Dividend Kings to consider today are AbbVie (NYSE: ABBV), 3M (NYSE: MMM), and Northwest Natural Holding (NYSE: NWN). AbbVie AbbVie announced on Oct. 29 that it would be increasing its dividend by 8.5%. AbbVie's streak of dividend increases will hit the 50-year mark next year if its time when the business was part... | And on a cash basis, the picture looks just as solid: AbbVie has generated $21.7 billion in free cash flow and paid out only $9 billion of that in dividends. Three Dividend Kings to consider today are AbbVie (NYSE: ABBV), 3M (NYSE: MMM), and Northwest Natural Holding (NYSE: NWN). AbbVie AbbVie announced on Oct. 29 that... | AbbVie's streak of dividend increases will hit the 50-year mark next year if its time when the business was part of Abbott Labs (it spun off in 2013) is included, which will also become a Dividend King in 2022. Three Dividend Kings to consider today are AbbVie (NYSE: ABBV), 3M (NYSE: MMM), and Northwest Natural Holding... | AbbVie AbbVie announced on Oct. 29 that it would be increasing its dividend by 8.5%. Northwest Natural's margins aren't as high as 3M's or AbbVie's, but at 11% over the trailing 12 months, the company has been generating a consistent profit. Three Dividend Kings to consider today are AbbVie (NYSE: ABBV), 3M (NYSE: MMM)... |
23,732 | 2021-12-30 00:00:00 UTC | AbbVie Is Much More than Humira | ABBV | https://www.nasdaq.com/articles/abbvie-is-much-more-than-humira | null | null | AbbVie (NYSE: ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company was spun off of Abbott Labs in 2013 with essentially one product to sell, Humira.
The company took the huge amounts of cash that was thrown off by Humira and invested more than $50 dollars into research and develop... | Today AbbVie has 48,000 employees and operates in the immunology, oncology, neuroscience, eye care, virology, woman’s health, and aesthetics spaces. In addition to carrying out research and development activities on its own, AbbVie has also done a great job using the cash flow from Humira to buy blockbuster drugs like ... | In addition to carrying out research and development activities on its own, AbbVie has also done a great job using the cash flow from Humira to buy blockbuster drugs like Rivoq and the Botox brand of cosmetic botulinum toxin, used to reduce skin wrinkles and treat migraine headaches. Wall Street’s Take Fourteen Wall St... | After reviewing AbbVie’s stock’s intrinsic value, the company’s plans to move past Humira, and what the Wall Street analysts and bloggers are saying, I am bullish on this stock. AbbVie has created a pipeline of pharmaceutical products that will act as a catalyst to drive the share price higher as investors realize that... | AbbVie has created a pipeline of pharmaceutical products that will act as a catalyst to drive the share price higher as investors realize that AbbVie is much more than the company that makes Humira. AbbVie (NYSE: ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. Today AbbVie has 48,000 emplo... |
23,733 | 2021-12-28 00:00:00 UTC | Abbvie Inc Shares Near 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-near-52-week-high-market-mover | null | null | Abbvie Inc (ABBV) shares closed today at 0.1% below its 52 week high of $134.48, giving the company a market cap of $237B. The stock is currently up 31.5% year-to-date, up 36.4% over the past 12 months, and up 170.6% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4... | Abbvie Inc (ABBV) shares closed today at 0.1% below its 52 week high of $134.48, giving the company a market cap of $237B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.1% below its 52 week high of $134.48, giving the company a market cap of $237B. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.1% below its 52 week high of $134.48, giving the company a market cap of $237B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.1% below its 52 week high of $134.48, giving the company a market cap of $237B. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,734 | 2021-12-28 00:00:00 UTC | AbbVie: Valuation, Debt, and Declining Margins Remain Risks | ABBV | https://www.nasdaq.com/articles/abbvie%3A-valuation-debt-and-declining-margins-remain-risks | null | null | AbbVie (ABBV) is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology. The company was founded on October 19, 2011, and is headquartered in North Chicago, IL.
Shares of AbbVie have gains of 25.9% in 2021 and have u... | AbbVie (ABBV) is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology. Shares of AbbVie have gains of 25.9% in 2021 and have underperformed the S&P 500, although the underperformance is marginal. I am bearish on AB... | AbbVie Business News Allergan Aesthetics, an AbbVie company, announced on December 16 that it had completed the acquisition of Soliton. AbbVie (ABBV) is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology. Shares ... | AbbVie Business News Allergan Aesthetics, an AbbVie company, announced on December 16 that it had completed the acquisition of Soliton. AbbVie has increased its dividend, but the dividend payout ratio is now considered too high. AbbVie (ABBV) is a biopharmaceutical company focused on key therapeutic areas like immunolo... | AbbVie has increased its dividend, but the dividend payout ratio is now considered too high. AbbVie (ABBV) is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology. Shares of AbbVie have gains of 25.9% in 2021 and h... |
23,735 | 2021-12-28 00:00:00 UTC | What AbbVie's Recent Drug News Means for Shareholders | ABBV | https://www.nasdaq.com/articles/what-abbvies-recent-drug-news-means-for-shareholders | null | null | At the end of last month, AbbVie (NYSE: ABBV) informed shareholders that it had submitted its application for Skyrizi to the European Medicines Agency (EMA) to treat patients aged 16 and older diagnosed with moderate to severe Crohn's disease.
But if Crohn's is approved as a third indication for the drug in the Europea... | At the end of last month, AbbVie (NYSE: ABBV) informed shareholders that it had submitted its application for Skyrizi to the European Medicines Agency (EMA) to treat patients aged 16 and older diagnosed with moderate to severe Crohn's disease. A significant market opportunity With a decision on Skyrizi's Crohn's diseas... | A significant market opportunity With a decision on Skyrizi's Crohn's disease application in the EU likely just months away, the question becomes: If the indication is approved based on clinical trial results, what financial impact would this have on AbbVie as a pharma stock? At the end of last month, AbbVie (NYSE: ABB... | A significant market opportunity With a decision on Skyrizi's Crohn's disease application in the EU likely just months away, the question becomes: If the indication is approved based on clinical trial results, what financial impact would this have on AbbVie as a pharma stock? At the end of last month, AbbVie (NYSE: ABB... | A significant market opportunity With a decision on Skyrizi's Crohn's disease application in the EU likely just months away, the question becomes: If the indication is approved based on clinical trial results, what financial impact would this have on AbbVie as a pharma stock? At the end of last month, AbbVie (NYSE: ABB... |
23,736 | 2021-12-27 00:00:00 UTC | 2 Top-Rated Biotech Stocks for 2022 | ABBV | https://www.nasdaq.com/articles/2-top-rated-biotech-stocks-for-2022 | null | null | In 2021, the biotech sector remained in the spotlight. It played a critical role in putting the pandemic under control by developing COVID-19 vaccinations.
In addition, the sector's expansion in 2021 was aided by solid quarterly results, new product introductions, and regular M&A activity.
The pandemic, however, is far... | AbbVie Second is AbbVie (ABBV), a biopharmaceutical firm that focuses on discovering and selling complete treatments for some of the world's most complex and severe diseases. AbbVie's revenue base has been broadened into new therapeutic areas as a result of the acquisition of Allergan, improving its long-term growth pr... | AbbVie has a Strong Buy consensus rating from Wall Street analysts, with 14 recent assessments, including 11 Buys and 3 Holds. AbbVie Second is AbbVie (ABBV), a biopharmaceutical firm that focuses on discovering and selling complete treatments for some of the world's most complex and severe diseases. AbbVie's revenue b... | AbbVie Second is AbbVie (ABBV), a biopharmaceutical firm that focuses on discovering and selling complete treatments for some of the world's most complex and severe diseases. AbbVie's revenue base has been broadened into new therapeutic areas as a result of the acquisition of Allergan, improving its long-term growth pr... | AbbVie Second is AbbVie (ABBV), a biopharmaceutical firm that focuses on discovering and selling complete treatments for some of the world's most complex and severe diseases. AbbVie's revenue base has been broadened into new therapeutic areas as a result of the acquisition of Allergan, improving its long-term growth pr... |
23,737 | 2021-12-26 00:00:00 UTC | 3 Dividend Stocks to Buy If the Market Crashes in 2022 | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-if-the-market-crashes-in-2022 | null | null | Market crashes happen, and they tend to drag down the best stocks along with the rest of the market. It's impossible to predict the timing and severity of the next downturn, but it's easy to imagine one occurring in the near term.
The omicron variant keeps threatening to pinch the global economy. If the latest variant ... | AbbVie The second half of 2021 has been disastrous for most drugmaker stocks, but not AbbVie (NYSE: ABBV). Over the past eight years, AbbVie's dividend has risen a whopping 253%, and at recent prices, the stock offers a tempting 4.3% yield. AbbVie has offered an above-average dividend since its inception because invest... | Over the past eight years, AbbVie's dividend has risen a whopping 253%, and at recent prices, the stock offers a tempting 4.3% yield. AbbVie The second half of 2021 has been disastrous for most drugmaker stocks, but not AbbVie (NYSE: ABBV). AbbVie has offered an above-average dividend since its inception because invest... | Johnson & Johnson Johnson & Johnson (NYSE: JNJ) shares haven't performed as well as Abbott's or AbbVie's this year. AbbVie The second half of 2021 has been disastrous for most drugmaker stocks, but not AbbVie (NYSE: ABBV). Over the past eight years, AbbVie's dividend has risen a whopping 253%, and at recent prices, the... | AbbVie The second half of 2021 has been disastrous for most drugmaker stocks, but not AbbVie (NYSE: ABBV). Over the past eight years, AbbVie's dividend has risen a whopping 253%, and at recent prices, the stock offers a tempting 4.3% yield. AbbVie has offered an above-average dividend since its inception because invest... |
23,738 | 2021-12-25 00:00:00 UTC | Abbvie Inc Shares Close in on 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-close-in-on-52-week-high-market-mover | null | null | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. The stock is currently up 30.2% year-to-date, up 35.1% over the past 12 months, and up 168.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2... | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,739 | 2021-12-24 00:00:00 UTC | Abbvie Inc Shares Approach 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-approach-52-week-high-market-mover-0 | null | null | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. The stock is currently up 30.2% year-to-date, up 35.0% over the past 12 months, and up 168.6% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1... | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.5% below its 52 week high of $133.77, giving the company a market cap of $235B. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 rose 1.2%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,740 | 2021-12-24 00:00:00 UTC | 3 Best Buffett Stocks to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/3-best-buffett-stocks-to-buy-for-the-long-haul | null | null | Since Warren Buffett took full control of Berkshire Hathaway in 1965, it became a diversified holding company with investments in publicly traded companies totaling nearly $345 billion at the time of writing.
The Oracle of Omaha's reputation of buying the highest quality businesses means that many individual investors ... | AbbVie Finally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE: ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able t... | Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able to stabilize and grow its net revenue beyond 2023. AbbVie Finally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE: ABBV). Berkshire currentl... | See the 10 stocks *Stock Advisor returns as of December 16, 2021 Kody Kester owns AbbVie, Bristol Myers Squibb, Johnson & Johnson, and Pfizer. AbbVie Finally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE: ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock. | AbbVie Finally, a Buffett stock that'd also be a good fit for income investors is AbbVie (NYSE: ABBV). Berkshire currently holds about $1.9 billion worth of AbbVie stock. Even though the immunology drug's U.S. sales made up 31% of AbbVie's $41.24 billion total year-to-date sales, the company's pipeline should be able t... |
23,741 | 2021-12-23 00:00:00 UTC | Interesting ABBV Put And Call Options For February 2022 | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-february-2022 | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the February 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new February 2022 contracts and identified one put and one call contract of particular interest.
The put... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $135.00 strike highlighted in red: Considering the fact that the $135.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $131.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $135.00 strike price has a current bid of $2.74. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new February 2022 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $135.00 strike highlighted in red: Consi... |
23,742 | 2021-12-23 00:00:00 UTC | iShares Core S&P Total U.S. Stock Market ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-core-sp-total-u.s.-stock-market-etf-experiences-big-inflow | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $295.6 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.8%, Coca-Cola Co (Symbol: KO) is up about 0.3%, and Chevron Corporation (Symbol: CVX) is higher by about 1.1%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year pric... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.8%, Coca-Cola Co (Symbol: KO) is up about 0.3%, and Chevron Corporation (Symbol: CVX) is higher by about 1.1%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year pric... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.8%, Coca-Cola Co (Symbol: KO) is up about 0.3%, and Chevron Corporation (Symbol: CVX) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of ITOT, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.8%, Coca-Cola Co (Symbol: KO) is up about 0.3%, and Chevron Corporation (Symbol: CVX) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
23,743 | 2021-12-23 00:00:00 UTC | Abbvie Inc Shares Approach 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-approach-52-week-high-market-mover | null | null | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $133.28, giving the company a market cap of $229B. The stock is currently up 27.1% year-to-date, up 31.3% over the past 12 months, and up 166.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0... | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $133.28, giving the company a market cap of $229B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $133.28, giving the company a market cap of $229B. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $133.28, giving the company a market cap of $229B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $133.28, giving the company a market cap of $229B. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,744 | 2021-12-22 00:00:00 UTC | Noteworthy Wednesday Option Activity: CF, CAMP, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-cf-camp-abbv | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in CF Industries Holdings Inc (Symbol: CF), where a total of 14,266 contracts have traded so far, representing approximately 1.4 million underlying shares. That amounts to about 51.5% of CF's average daily trading ... | Especially high volume was seen for the $105 strike put option expiring February 18, 2022, with 2,505 contracts trading so far today, representing approximately 250,500 underlying shares of ABBV. Below is a chart showing CAMP's trailing twelve month trading history, with the $7.50 strike highlighted in orange: And AbbV... | Below is a chart showing CAMP's trailing twelve month trading history, with the $7.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 35,778 contracts thus far today. That number of contracts represents approximately 3.6 million underlying shares, working out to a sizeable 49... | Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: For the various different available expirations for CF options, CAMP options, or ABBV options, visit StockOptionsChannel.com. Below is a chart showing CAMP's trailing twelve month trading history, with the... | That number of contracts represents approximately 3.6 million underlying shares, working out to a sizeable 49.5% of ABBV's average daily trading volume over the past month, of 7.2 million shares. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: For the v... |
23,745 | 2021-12-22 00:00:00 UTC | 3 of the Best Biotech Stocks for 2022 to Buy Now | ABBV | https://www.nasdaq.com/articles/3-of-the-best-biotech-stocks-for-2022-to-buy-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The coronavirus is kicking back into gear again, with investors licking their lips over biotech stocks. The omicron variant has roiled the world, which makes biotech’s the most pertinent investment option at this time.
Naturally, most of the market-leading ... | Here are three top biotech stocks to buy for 2022: Pfizer (NYSE:PFE) AbbVie (NYSE:ABBV) Novavax (NASDAQ:NVAX) Best Biotech Stocks To Buy: Pfizer (PFE) PFE) logo on the windows of a corporate building" width="300" height="169"> Source: photobyphm / Shutterstock.com Pfizer struggled before the pandemic, with an unattract... | Here are three top biotech stocks to buy for 2022: Pfizer (NYSE:PFE) AbbVie (NYSE:ABBV) Novavax (NASDAQ:NVAX) Best Biotech Stocks To Buy: Pfizer (PFE) PFE) logo on the windows of a corporate building" width="300" height="169"> Source: photobyphm / Shutterstock.com Pfizer struggled before the pandemic, with an unattract... | Here are three top biotech stocks to buy for 2022: Pfizer (NYSE:PFE) AbbVie (NYSE:ABBV) Novavax (NASDAQ:NVAX) Best Biotech Stocks To Buy: Pfizer (PFE) PFE) logo on the windows of a corporate building" width="300" height="169"> Source: photobyphm / Shutterstock.com Pfizer struggled before the pandemic, with an unattract... | ABBV stock is one of the most attractive biotech stocks out there. Here are three top biotech stocks to buy for 2022: Pfizer (NYSE:PFE) AbbVie (NYSE:ABBV) Novavax (NASDAQ:NVAX) Best Biotech Stocks To Buy: Pfizer (PFE) PFE) logo on the windows of a corporate building" width="300" height="169"> Source: photobyphm / Shutt... |
23,746 | 2021-12-22 00:00:00 UTC | Got $1,000? These 3 Stocks Are Still Absurdly Cheap | ABBV | https://www.nasdaq.com/articles/got-%241000-these-3-stocks-are-still-absurdly-cheap | null | null | Let's face it: Many stocks are ridiculously expensive. Even after the recent pullback, the S&P 500 index remains only 3% or so below its all-time high. The Shiller cyclically adjusted price-to-earnings (CAPE) ratio for the index is at its highest level since 2000.
But some stocks are definite outliers. If you've got $1... | AbbVie Another drugmaker isn't quite as inexpensive as Viatris but still sports a quite attractive valuation. AbbVie's (NYSE: ABBV) shares trade below nine times expected earnings. Is the loss of U.S. exclusivity for top-selling Humira in 2023 enough to warrant AbbVie's bargain price tag? | AbbVie Another drugmaker isn't quite as inexpensive as Viatris but still sports a quite attractive valuation. AbbVie's (NYSE: ABBV) shares trade below nine times expected earnings. Is the loss of U.S. exclusivity for top-selling Humira in 2023 enough to warrant AbbVie's bargain price tag? | See the 10 stocks *Stock Advisor returns as of December 16, 2021 Keith Speights owns AbbVie, Enterprise Products Partners, and Viatris. AbbVie Another drugmaker isn't quite as inexpensive as Viatris but still sports a quite attractive valuation. AbbVie's (NYSE: ABBV) shares trade below nine times expected earnings. | AbbVie Another drugmaker isn't quite as inexpensive as Viatris but still sports a quite attractive valuation. AbbVie's (NYSE: ABBV) shares trade below nine times expected earnings. Is the loss of U.S. exclusivity for top-selling Humira in 2023 enough to warrant AbbVie's bargain price tag? |
23,747 | 2021-12-21 00:00:00 UTC | Why CytomX Therapeutics Stock Is Crashing Today | ABBV | https://www.nasdaq.com/articles/why-cytomx-therapeutics-stock-is-crashing-today | null | null | What happened
Shares of CytomX Therapeutics (NASDAQ: CTMX) were crashing 40.1% lower as of 11:44 a.m. ET on Tuesday. The steep decline came after the company announced disappointing preliminary results from a phase 2 study evaluating CX-2029 in treating patients with either advanced squamous non-small cell lung cancer ... | Now what CytomX and AbbVie are continuing enrollment in the phase 2 study of patients with lung cancer. CX-2029 is an antibody-drug conjugate that's being co-developed by CytomX and AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of December 16, 2021 Keith Speights owns AbbVie. | CX-2029 is an antibody-drug conjugate that's being co-developed by CytomX and AbbVie (NYSE: ABBV). Now what CytomX and AbbVie are continuing enrollment in the phase 2 study of patients with lung cancer. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Keith Speights owns AbbVie. | CX-2029 is an antibody-drug conjugate that's being co-developed by CytomX and AbbVie (NYSE: ABBV). Now what CytomX and AbbVie are continuing enrollment in the phase 2 study of patients with lung cancer. See the 10 stocks *Stock Advisor returns as of December 16, 2021 Keith Speights owns AbbVie. | Now what CytomX and AbbVie are continuing enrollment in the phase 2 study of patients with lung cancer. CX-2029 is an antibody-drug conjugate that's being co-developed by CytomX and AbbVie (NYSE: ABBV). See the 10 stocks *Stock Advisor returns as of December 16, 2021 Keith Speights owns AbbVie. |
23,748 | 2021-12-21 00:00:00 UTC | Better Buy: Viatris vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-buy%3A-viatris-vs.-abbvie | null | null | With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unpr... | With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unpr... | But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unprofitable may not deter investors. With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan Ab... | With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. For the time being, AbbVie's forward dividend yield of 4.33% is a convincing reason for investors to buy the stock or stick around through t... | With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unpr... |
23,749 | 2021-12-18 00:00:00 UTC | 3 Reasons Why This Healthcare Stock Is a Long-Term Buy | ABBV | https://www.nasdaq.com/articles/3-reasons-why-this-healthcare-stock-is-a-long-term-buy | null | null | If you think about it, discovering new treatments in healthcare can be similar to building a sound investment portfolio. A great deal of time is spent on research and monitoring, finding the right mix, and then waiting for that magical day. For pharmaceutical companies, that day might come when a product is approved or... | Research-based pharmaceutical company AbbVie (NYSE: ABBV) is experiencing the excitement of U.S. Food and Drug Administration (FDA) approvals while also carrying an honored distinction of being a Dividend Aristocrat, combining to give investors three good reasons to consider it part of their long-term investment strate... | FDA-approved eye drops are a first-of-their-kind On Dec. 9, AbbVie celebrated the announcement of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat age-related blurry vision (presbyopia). This Aristocrat's yield crushes other healthcare companies in the S&P 500 In addition to FDA ... | FDA-approved eye drops are a first-of-their-kind On Dec. 9, AbbVie celebrated the announcement of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat age-related blurry vision (presbyopia). This Aristocrat's yield crushes other healthcare companies in the S&P 500 In addition to FDA ... | FDA-approved eye drops are a first-of-their-kind On Dec. 9, AbbVie celebrated the announcement of its Vuity 1.25% prescription eye drop, the first and only FDA-approved eye drop to treat age-related blurry vision (presbyopia). This Aristocrat's yield crushes other healthcare companies in the S&P 500 In addition to FDA ... |
23,750 | 2021-12-18 00:00:00 UTC | What to Make of the FDA's Latest Warning to AbbVie and Pfizer | ABBV | https://www.nasdaq.com/articles/what-to-make-of-the-fdas-latest-warning-to-abbvie-and-pfizer | null | null | The U.S. Food and Drug Administration (FDA) has placed additional warnings on the labels for JAK inhibitors marketed by AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). In this Motley Fool Live video recorded on Dec. 8, 2021, Motley Fool contributors Keith Speights and Brian Orelli talk about what to make of the FDA's lates... | But the FDA has signaled that it believes it's a class effect and so they -- it seems likely that AbbVie's Rinvoq was going to get a warning label, too. The U.S. Food and Drug Administration (FDA) has placed additional warnings on the labels for JAK inhibitors marketed by AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). The... | The U.S. Food and Drug Administration (FDA) has placed additional warnings on the labels for JAK inhibitors marketed by AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). The FDA has slapped additional warnings on AbbVie's JAK inhibitor, Rinvoq, and Pfizer's JAK inhibitor, Xeljanz. I'm not sure the warning labels in and of th... | The U.S. Food and Drug Administration (FDA) has placed additional warnings on the labels for JAK inhibitors marketed by AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE). The FDA has slapped additional warnings on AbbVie's JAK inhibitor, Rinvoq, and Pfizer's JAK inhibitor, Xeljanz. I'm not sure the warning labels in and of th... | The FDA has slapped additional warnings on AbbVie's JAK inhibitor, Rinvoq, and Pfizer's JAK inhibitor, Xeljanz. I'm not sure the warning labels in and of themselves were that big of a deal since it was already known, and obviously, AbbVie was hoping that it wouldn't get a warning label since it was only the issues we'r... |
23,751 | 2021-12-16 00:00:00 UTC | 5 Biotech Stocks For Your Late December 2021 Watchlist | ABBV | https://www.nasdaq.com/articles/5-biotech-stocks-for-your-late-december-2021-watchlist | null | null | 5 Biotech Stocks To Check Out Before The End Of 2021
With the coronavirus pandemic kicking back into full swing, biotech stocks are once again at the forefront. For one thing, this part of thestock market todayhas and continues to work towards dealing with the pandemic. Now, as the Omicron variant sweeps the globe, I c... | Top Biotech Stocks To Watch This Week Calliditas Therapeutics (NASDAQ: CALT) Valneva SE (NASDAQ: VALN) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Calliditas Therapeutics Calliditas is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatm... | Top Biotech Stocks To Watch This Week Calliditas Therapeutics (NASDAQ: CALT) Valneva SE (NASDAQ: VALN) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Calliditas Therapeutics Calliditas is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatm... | Top Biotech Stocks To Watch This Week Calliditas Therapeutics (NASDAQ: CALT) Valneva SE (NASDAQ: VALN) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Calliditas Therapeutics Calliditas is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatm... | Top Biotech Stocks To Watch This Week Calliditas Therapeutics (NASDAQ: CALT) Valneva SE (NASDAQ: VALN) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Pfizer Inc. (NYSE: PFE) Calliditas Therapeutics Calliditas is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel treatm... |
23,752 | 2021-12-16 00:00:00 UTC | Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson? | ABBV | https://www.nasdaq.com/articles/unstoppable-dividend-king-for-2022%3A-abbvie-or-johnson-johnson | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. They're both large-cap stocks in the healthcare space that are also Dividend Kings. Both appear to be undervalued based on their current and expected future earnings. They're the type of steady, long-term investments that retirees and ot... | What's more, Humira's sales won't necessarily crater after it loses patent exclusivity in the U.S. A good comparison is Botox, which already has plenty of competition, yet it continues to produce strong numbers for AbbVie. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. The case for A... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. The case for AbbVie Since splitting off from Abbott Laboratories in 2013, AbbVie has seen revenue increase steadily -- up 115% over the past five years -- and it has been up every year. AbbVie is best-known for the world's biggest-sellin... | The case for AbbVie Since splitting off from Abbott Laboratories in 2013, AbbVie has seen revenue increase steadily -- up 115% over the past five years -- and it has been up every year. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. AbbVie is best-known for the world's biggest-sellin... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) have plenty of similarities. The case for AbbVie Since splitting off from Abbott Laboratories in 2013, AbbVie has seen revenue increase steadily -- up 115% over the past five years -- and it has been up every year. AbbVie is best-known for the world's biggest-sellin... |
23,753 | 2021-12-15 00:00:00 UTC | Noteworthy ETF Inflows: DLN, ABBV, MRK, KO | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-dln-abbv-mrk-ko | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the WisdomTree U.S. LargeCap Dividend Fund (Symbol: DLN) where we have detected an approximate $334.7 million dollar inflow -- that's a 10.2% increase week over week in outstanding units (from 2... | Among the largest underlying components of DLN, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and Coca-Cola Co (Symbol: KO) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of DLN, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and Coca-Cola Co (Symbol: KO) is higher by about 0.1%. For a complete list of holdings, visit the DLN Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of DLN, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and Coca-Cola Co (Symbol: KO) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of DLN, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.5%, Merck & Co Inc (Symbol: MRK) is up about 0.8%, and Coca-Cola Co (Symbol: KO) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
23,754 | 2021-12-15 00:00:00 UTC | 5 Top Healthcare Dividend Stocks To Watch Today | ABBV | https://www.nasdaq.com/articles/5-top-healthcare-dividend-stocks-to-watch-today | null | null | Check Out These Healthcare Dividend Stocks In The Stock Market Today
Inflation is becoming the hot new word when it comes to the stock market. Now, like it or not, it seems like inflation will be with us for a while. Sure, you could join the crowd and park your money in Apple (NASDAQ: AAPL). After all, Apple is deemed ... | Best Healthcare Dividend Stocks To Watch Right Now AbbVie Inc. (NYSE: ABBV) Medical Properties Trust Inc. (NYSE: MPW) Royalty Pharma plc (NASDAQ: RPRX) CVS Health Corp. (NYSE: CVS) Amgen Inc. (NASDAQ: AMGN) AbbVie Pharmaceutical giant AbbVie is an attractive income play for many investors. Among the core areas of AbbVi... | Best Healthcare Dividend Stocks To Watch Right Now AbbVie Inc. (NYSE: ABBV) Medical Properties Trust Inc. (NYSE: MPW) Royalty Pharma plc (NASDAQ: RPRX) CVS Health Corp. (NYSE: CVS) Amgen Inc. (NASDAQ: AMGN) AbbVie Pharmaceutical giant AbbVie is an attractive income play for many investors. Among the core areas of AbbVi... | Best Healthcare Dividend Stocks To Watch Right Now AbbVie Inc. (NYSE: ABBV) Medical Properties Trust Inc. (NYSE: MPW) Royalty Pharma plc (NASDAQ: RPRX) CVS Health Corp. (NYSE: CVS) Amgen Inc. (NASDAQ: AMGN) AbbVie Pharmaceutical giant AbbVie is an attractive income play for many investors. Among the core areas of AbbVi... | Best Healthcare Dividend Stocks To Watch Right Now AbbVie Inc. (NYSE: ABBV) Medical Properties Trust Inc. (NYSE: MPW) Royalty Pharma plc (NASDAQ: RPRX) CVS Health Corp. (NYSE: CVS) Amgen Inc. (NASDAQ: AMGN) AbbVie Pharmaceutical giant AbbVie is an attractive income play for many investors. Among the core areas of AbbVi... |
23,755 | 2021-12-14 00:00:00 UTC | FDA Approves AbbVie's RINVOQ To Treat Active Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-rinvoq-to-treat-active-psoriatic-arthritis | null | null | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers.
The FDA approval is supported by d... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Psoriatic arthritis is a heterogen... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval is supported by d... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval is supported by d... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. The FDA approval is supported by d... |
23,756 | 2021-12-14 00:00:00 UTC | 2 Warren Buffett Dividend Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/2-warren-buffett-dividend-stocks-to-buy-right-now | null | null | Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a sustainable business model, and strong free cash flows.
As a result, most of Berkshire's top holdings over the past sev... | Although Buffett's diversified holding company has since pared back its position in the Illinois-based drugmaker, AbbVie's shares are still a worthwhile buy for most income investors. The healthcare stocks AbbVie (NYSE: ABBV) and Royalty Pharma (NASDAQ: RPRX) are two intriguing Berkshire holdings that each pay a respec... | The healthcare stocks AbbVie (NYSE: ABBV) and Royalty Pharma (NASDAQ: RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. A... | The healthcare stocks AbbVie (NYSE: ABBV) and Royalty Pharma (NASDAQ: RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. A... | The healthcare stocks AbbVie (NYSE: ABBV) and Royalty Pharma (NASDAQ: RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. A... |
23,757 | 2021-12-14 00:00:00 UTC | Why Soliton Popped While the Market Slid Today | ABBV | https://www.nasdaq.com/articles/why-soliton-popped-while-the-market-slid-today | null | null | What happened
On a gloomy day for the stock market, healthcare aesthetics specialist Soliton (NASDAQ: SOLY) was a luminous bright spot on Tuesday. The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is about to close.
So what
Soliton pointed out in a r... | The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is about to close. So what Soliton pointed out in a regulatory filing this morning that the waiting period mandated under law for deals like AbbVie's acquisition expired Monday night. The two companie... | The two companies agreed that AbbVie's Allergan Aesthetics unit would acquire Soliton and its RESONIC device for $22.60 per share; all told, the enterprise value of the deal is around $550 million. The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is... | The two companies agreed that AbbVie's Allergan Aesthetics unit would acquire Soliton and its RESONIC device for $22.60 per share; all told, the enterprise value of the deal is around $550 million. The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is... | The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is about to close. So what Soliton pointed out in a regulatory filing this morning that the waiting period mandated under law for deals like AbbVie's acquisition expired Monday night. The two companie... |
23,758 | 2021-12-14 00:00:00 UTC | Is It Too Late to Buy AbbVie Stock? | ABBV | https://www.nasdaq.com/articles/is-it-too-late-to-buy-abbvie-stock | null | null | Past performance isn't a guarantee of future success, and that's as true in life as it is in the stock market. But past performance isn't meaningless either; investing in a company capable of replicating a winning strategy is a pretty good bet. With that in mind, let's look at pharma giant AbbVie (NYSE: ABBV).
Unlike m... | Products such as immunosuppressants Skyrizi and Rinvoq, cancer drug Venclexta, and skin treatment Botox (added to the lineup through AbbVie's $63 billion acquisition of Allergan) are all performing well. These two assets are either approved, under regulatory review, or in late-stage development across all of Humira's m... | ABBV data by YCharts Results remain strong On the financial front, AbbVie's business seems pretty healthy. With that in mind, let's look at pharma giant AbbVie (NYSE: ABBV). The bears will point to declining sales of AbbVie's rheumatoid arthritis drug Humira in Europe as evidence that its growth days are well behind it... | The bears will point to declining sales of AbbVie's rheumatoid arthritis drug Humira in Europe as evidence that its growth days are well behind it. Meanwhile, sales within AbbVie's oncology segment rose 8.4% year over year to $1.9 billion. Products such as immunosuppressants Skyrizi and Rinvoq, cancer drug Venclexta, a... | With that in mind, let's look at pharma giant AbbVie (NYSE: ABBV). The bears will point to declining sales of AbbVie's rheumatoid arthritis drug Humira in Europe as evidence that its growth days are well behind it. Let's consider whether it's still worth purchasing AbbVie's shares today. |
23,759 | 2021-12-13 00:00:00 UTC | Noteworthy Monday Option Activity: ADBE, EXPE, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-monday-option-activity%3A-adbe-expe-abbv | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 25,946 contracts have traded so far, representing approximately 2.6 million underlying shares. That amounts to about 96.7% of ADBE's average daily trading volume over the pa... | Especially high volume was seen for the $131 strike call option expiring December 17, 2021, with 7,659 contracts trading so far today, representing approximately 765,900 underlying shares of ABBV. Below is a chart showing EXPE's trailing twelve month trading history, with the $170 strike highlighted in orange: And AbbV... | Below is a chart showing EXPE's trailing twelve month trading history, with the $170 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 41,900 contracts, representing approximately 4.2 million underlying shares or approximately 74.2% of ABBV's average daily trading volume over the... | Below is a chart showing EXPE's trailing twelve month trading history, with the $170 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 41,900 contracts, representing approximately 4.2 million underlying shares or approximately 74.2% of ABBV's average daily trading volume over the... | Below is a chart showing EXPE's trailing twelve month trading history, with the $170 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 41,900 contracts, representing approximately 4.2 million underlying shares or approximately 74.2% of ABBV's average daily trading volume over the... |
23,760 | 2021-12-13 00:00:00 UTC | AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch | ABBV | https://www.nasdaq.com/articles/astrazeneca-elated-on-calquence-data-imgns-imgn632-appears-to-be-promising-in-aml-xrtx-on | null | null | (RTTNews) - Today's Daily Dose brings you news about AstraZeneca's new long-term data related to cancer drug Calquence; superior efficacy of Novartis' Scemblix compared to Bosulif in chronic myeloid leukemia; and ImmunoGen's updated initial safety and efficacy findings from its phase 1b/2 study of IMGN632 in combinatio... | The ELEVATE-RR trial is a phase III non-inferiority trial of Calquence versus AbbVie's approved drug Ibrutinib (Imbruvica) in patients with relapsed or refractory CLL after at least one prior therapy. AbbVie Inc. (ABBV) closed at a new high of $125.47, up 1.06%. ASCEND is a phase III trial that evaluated the efficacy a... | The ELEVATE-RR trial is a phase III non-inferiority trial of Calquence versus AbbVie's approved drug Ibrutinib (Imbruvica) in patients with relapsed or refractory CLL after at least one prior therapy. AbbVie Inc. (ABBV) closed at a new high of $125.47, up 1.06%. (RTTNews) - Today's Daily Dose brings you news about Astr... | The ELEVATE-RR trial is a phase III non-inferiority trial of Calquence versus AbbVie's approved drug Ibrutinib (Imbruvica) in patients with relapsed or refractory CLL after at least one prior therapy. AbbVie Inc. (ABBV) closed at a new high of $125.47, up 1.06%. (RTTNews) - Today's Daily Dose brings you news about Astr... | AbbVie Inc. (ABBV) closed at a new high of $125.47, up 1.06%. The ELEVATE-RR trial is a phase III non-inferiority trial of Calquence versus AbbVie's approved drug Ibrutinib (Imbruvica) in patients with relapsed or refractory CLL after at least one prior therapy. (RTTNews) - Today's Daily Dose brings you news about Astr... |
23,761 | 2021-12-11 00:00:00 UTC | 3 Best Dividend Stocks That Wall Street Is Sleeping On | ABBV | https://www.nasdaq.com/articles/3-best-dividend-stocks-that-wall-street-is-sleeping-on | null | null | If you're an income-minded investor, you've been out of luck for a long while now. Not only have interest rates been unusually low since we recovered from the subprime crisis back in 2009, but it has also kept dividend yields similarly suppressed -- even as growth stocks have also dramatically outperformed.
That doesn'... | AbbVie Dividend yield: 4.6% Shares of drugmaker AbbVie (NYSE: ABBV) haven't suffered the same losing performance this year that Western Union's stock has. AbbVie is the name behind cancer-fighting therapies like Imbruvica, facial treatment Botox, and a slew of other products. That'll take a big bite out of AbbVie's tot... | AbbVie Dividend yield: 4.6% Shares of drugmaker AbbVie (NYSE: ABBV) haven't suffered the same losing performance this year that Western Union's stock has. AbbVie is the name behind cancer-fighting therapies like Imbruvica, facial treatment Botox, and a slew of other products. That'll take a big bite out of AbbVie's tot... | AbbVie Dividend yield: 4.6% Shares of drugmaker AbbVie (NYSE: ABBV) haven't suffered the same losing performance this year that Western Union's stock has. AbbVie is the name behind cancer-fighting therapies like Imbruvica, facial treatment Botox, and a slew of other products. That'll take a big bite out of AbbVie's tot... | AbbVie Dividend yield: 4.6% Shares of drugmaker AbbVie (NYSE: ABBV) haven't suffered the same losing performance this year that Western Union's stock has. AbbVie is the name behind cancer-fighting therapies like Imbruvica, facial treatment Botox, and a slew of other products. That'll take a big bite out of AbbVie's tot... |
23,762 | 2021-12-10 00:00:00 UTC | Drugmakers aim big price hikes at U.S. patients -congressional report | ABBV | https://www.nasdaq.com/articles/drugmakers-aim-big-price-hikes-at-u.s.-patients-congressional-report | null | null | By Diane Bartz
WASHINGTON, Dec 10 (Reuters) - Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co LLY.N, Novo Nordisk NOVOb.CO and Sanofi SASY.PA, which control the market for in... | The report also found price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now own... | The report also found price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now own... | The report also found price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now own... | The report also found price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now own... |
23,763 | 2021-12-10 00:00:00 UTC | Drugmakers aim big price hikes at U.S. patients, congressional report finds | ABBV | https://www.nasdaq.com/articles/drugmakers-aim-big-price-hikes-at-u.s.-patients-congressional-report-finds | null | null | By Diane Bartz
WASHINGTON, Dec 10 (Reuters) - Drugmakers have targeted the U.S. market to earn outsized profits from old medicines, according to a report released on Friday by the House Oversight Committee that highlighted Eli Lilly and Co LLY.N, Novo Nordisk NOVOb.CO and Sanofi SASY.PA, which dominate the market for i... | The report also listed price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades-old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now ow... | The report also listed price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades-old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now ow... | The report also listed price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades-old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now ow... | The report also listed price hikes of 825% for Teva Pharmaceutical Industries' TEVA.TA Copaxone, 486% for Amgen's AMGN.O Enbrel, 395% for Novartis' NOVN.S decades-old Gleevec, more than 100,000% for Mallinckrodt's Acthar, 471% for AbbVie's ABBV.N Humira and 82% for its Imbruvica, and 255% for Celgene's Revlimid, now ow... |
23,764 | 2021-12-10 00:00:00 UTC | 4 Stocks That Could Be Worth $1 Trillion by 2035 | ABBV | https://www.nasdaq.com/articles/4-stocks-that-could-be-worth-%241-trillion-by-2035 | null | null | How do you know that a stock has truly made it? I would argue that reaching the $1 trillion market capitalization milestone is the telltale sign that a stock has achieved something very special. At present, there are just six such companies, but no doubt others will begin to reach those lofty heights in the years to co... | Key products in that group include immunology blockbusters Stelara and Tremfya as well as cancer drugs Darzalex and Imbruvica (co-owned with AbbVie). See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie, Broadcom Ltd, Johnson & Johnson, UnitedHealth Group, and Visa. While b... | Key products in that group include immunology blockbusters Stelara and Tremfya as well as cancer drugs Darzalex and Imbruvica (co-owned with AbbVie). See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie, Broadcom Ltd, Johnson & Johnson, UnitedHealth Group, and Visa. As the ... | Key products in that group include immunology blockbusters Stelara and Tremfya as well as cancer drugs Darzalex and Imbruvica (co-owned with AbbVie). See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie, Broadcom Ltd, Johnson & Johnson, UnitedHealth Group, and Visa. That's ... | Key products in that group include immunology blockbusters Stelara and Tremfya as well as cancer drugs Darzalex and Imbruvica (co-owned with AbbVie). See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie, Broadcom Ltd, Johnson & Johnson, UnitedHealth Group, and Visa. The fir... |
23,765 | 2021-12-09 00:00:00 UTC | Allergan Announces Availability Of FDA-Approved Eye Drop VUITY - Quick Facts | ABBV | https://www.nasdaq.com/articles/allergan-announces-availability-of-fda-approved-eye-drop-vuity-quick-facts | null | null | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies across the U.S.
The FDA approval of VUITY in ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies across the U.S. VUITY is an optimized formula... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies across the U.S. The FDA approval of VUITY in ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies across the U.S. The FDA approval of VUITY in ... | (RTTNews) - Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug Administration (FDA) to treat presbyopia, is now available by prescription in pharmacies across the U.S. Presbyopia, or age-related bl... |
23,766 | 2021-12-09 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-2 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow ... | Get the latest Zacks research report on ABBV — FREE Get the latest Zacks research report on SJM — FREE Dividend Growth Stocks: 25 Aristocrats » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Cardinal Health, Inc. (Symbol: CAH) $48.25... | Cardinal Health, Inc. (Symbol: CAH) $48.25 $58.78 21.82% General Dynamics Corp (Symbol: GD) $200.88 $234.44 16.71% Cincinnati Financial Corp. (Symbol: CINF) $117.21 $135.00 15.18% AbbVie Inc (Symbol: ABBV) $121.87 $133.08 9.20% J.M. Cardinal Health, Inc. (Symbol: CAH) 4.07% 21.82% 25.89% General Dynamics Corp (Symbol: ... | Cardinal Health, Inc. (Symbol: CAH) $48.25 $58.78 21.82% General Dynamics Corp (Symbol: GD) $200.88 $234.44 16.71% Cincinnati Financial Corp. (Symbol: CINF) $117.21 $135.00 15.18% AbbVie Inc (Symbol: ABBV) $121.87 $133.08 9.20% J.M. Cardinal Health, Inc. (Symbol: CAH) 4.07% 21.82% 25.89% General Dynamics Corp (Symbol: ... | Cardinal Health, Inc. (Symbol: CAH) $48.25 $58.78 21.82% General Dynamics Corp (Symbol: GD) $200.88 $234.44 16.71% Cincinnati Financial Corp. (Symbol: CINF) $117.21 $135.00 15.18% AbbVie Inc (Symbol: ABBV) $121.87 $133.08 9.20% J.M. Cardinal Health, Inc. (Symbol: CAH) 4.07% 21.82% 25.89% General Dynamics Corp (Symbol: ... |
23,767 | 2021-12-08 00:00:00 UTC | AbbVie settles New York opioid case for $200 mln as trial winds down | ABBV | https://www.nasdaq.com/articles/abbvie-settles-new-york-opioid-case-for-%24200-mln-as-trial-winds-down | null | null | By Brendan Pierson
Dec 8 (Reuters) - Drugmaker AbbVie Inc ABBV.N agreed to pay $200 million to settle claims by New York that it helped fuel an epidemic of opioid addiction in the state, on the day jurors were expected to hear closing arguments at the end of a five-month trial.
New York Attorney General Letitia James a... | By Brendan Pierson Dec 8 (Reuters) - Drugmaker AbbVie Inc ABBV.N agreed to pay $200 million to settle claims by New York that it helped fuel an epidemic of opioid addiction in the state, on the day jurors were expected to hear closing arguments at the end of a five-month trial. James, along with New York's Nassau and S... | By Brendan Pierson Dec 8 (Reuters) - Drugmaker AbbVie Inc ABBV.N agreed to pay $200 million to settle claims by New York that it helped fuel an epidemic of opioid addiction in the state, on the day jurors were expected to hear closing arguments at the end of a five-month trial. James, along with New York's Nassau and S... | By Brendan Pierson Dec 8 (Reuters) - Drugmaker AbbVie Inc ABBV.N agreed to pay $200 million to settle claims by New York that it helped fuel an epidemic of opioid addiction in the state, on the day jurors were expected to hear closing arguments at the end of a five-month trial. James, along with New York's Nassau and S... | By Brendan Pierson Dec 8 (Reuters) - Drugmaker AbbVie Inc ABBV.N agreed to pay $200 million to settle claims by New York that it helped fuel an epidemic of opioid addiction in the state, on the day jurors were expected to hear closing arguments at the end of a five-month trial. James, along with New York's Nassau and S... |
23,768 | 2021-12-08 00:00:00 UTC | AbbVie Stock: Strong Dividend Growth and Reasonably Valued | ABBV | https://www.nasdaq.com/articles/abbvie-stock%3A-strong-dividend-growth-and-reasonably-valued | null | null | AbbVie (ABBV) is an international, research-driven biopharmaceutical company specializing in developing and marketing comprehensive therapies that aim to remedy some of the world's most complicated and severe diseases.
Following AbbVie's acquisition of Allergan plc last year, the company has formed a diversified biopha... | AbbVie (ABBV) is an international, research-driven biopharmaceutical company specializing in developing and marketing comprehensive therapies that aim to remedy some of the world's most complicated and severe diseases. In fact, the combination of AbbVie's original product portfolio and its enhanced pipeline following a... | (See Analysts' Top Stocks on TipRanks) Q3 Results: Another Steady Quarter AbbVie's Q3 results came in quite strong, with the company generating revenues of $14.3 billion during the period, an 11.3% increase year-over-year. Wall Street's Take Turning to Wall Street, AbbVie has a Strong Buy consensus rating, based on ten... | (See Analysts' Top Stocks on TipRanks) Q3 Results: Another Steady Quarter AbbVie's Q3 results came in quite strong, with the company generating revenues of $14.3 billion during the period, an 11.3% increase year-over-year. Regarding future profitability growth, note that AbbVie's management believes that despite Humira... | Following AbbVie's acquisition of Allergan plc last year, the company has formed a diversified biopharmaceutical product portfolio. AbbVie (ABBV) is an international, research-driven biopharmaceutical company specializing in developing and marketing comprehensive therapies that aim to remedy some of the world's most co... |
23,769 | 2021-12-08 00:00:00 UTC | Jury to hear final arguments in N.Y. opioid case against drugmakers | ABBV | https://www.nasdaq.com/articles/jury-to-hear-final-arguments-in-n.y.-opioid-case-against-drugmakers | null | null | By Brendan Pierson
Dec 8 (Reuters) - Jurors in a New York state court are expected to hear closing arguments Wednesday over whether drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA fueled an opioid epidemic in the state, concluding a trial that has lasted more than five months.
New York's Att... | By Brendan Pierson Dec 8 (Reuters) - Jurors in a New York state court are expected to hear closing arguments Wednesday over whether drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA fueled an opioid epidemic in the state, concluding a trial that has lasted more than five months. The case is on... | By Brendan Pierson Dec 8 (Reuters) - Jurors in a New York state court are expected to hear closing arguments Wednesday over whether drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA fueled an opioid epidemic in the state, concluding a trial that has lasted more than five months. The case is on... | By Brendan Pierson Dec 8 (Reuters) - Jurors in a New York state court are expected to hear closing arguments Wednesday over whether drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA fueled an opioid epidemic in the state, concluding a trial that has lasted more than five months. The case is on... | By Brendan Pierson Dec 8 (Reuters) - Jurors in a New York state court are expected to hear closing arguments Wednesday over whether drugmakers AbbVie Inc ABBV.N and Teva Pharmaceutical Industries Ltd TEVA.TA fueled an opioid epidemic in the state, concluding a trial that has lasted more than five months. New York's Att... |
23,770 | 2021-12-07 00:00:00 UTC | What This Label Expansion Means for Pfizer | ABBV | https://www.nasdaq.com/articles/what-this-label-expansion-means-for-pfizer | null | null | Last month, Pfizer (NYSE: PFE) announced that the European Commission (E.C.) had authorized the company's Xeljanz immunology drug to treat adult ankylosing spondylitis -- a kind of arthritis affecting the spine and large joints -- if patients had failed at least one other therapy.
Why did the E.C. approve Xeljanz for i... | Xeljanz's 40.6% rate of pain reduction was a bit below the 45% rate for AbbVie's (NYSE: ABBV) Rinvoq. See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie and Pfizer. had authorized the company's Xeljanz immunology drug to treat adult ankylosing spondylitis -- a kind of art... | Xeljanz's 40.6% rate of pain reduction was a bit below the 45% rate for AbbVie's (NYSE: ABBV) Rinvoq. See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie and Pfizer. had authorized the company's Xeljanz immunology drug to treat adult ankylosing spondylitis -- a kind of art... | Xeljanz's 40.6% rate of pain reduction was a bit below the 45% rate for AbbVie's (NYSE: ABBV) Rinvoq. See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie and Pfizer. had authorized the company's Xeljanz immunology drug to treat adult ankylosing spondylitis -- a kind of art... | Xeljanz's 40.6% rate of pain reduction was a bit below the 45% rate for AbbVie's (NYSE: ABBV) Rinvoq. See the 10 stocks *Stock Advisor returns as of November 10, 2021 Kody Kester owns shares of AbbVie and Pfizer. 's recent approval -- Xeljanz could be a critical treatment for many ankylosing spondylitis patients in the... |
23,771 | 2021-12-07 00:00:00 UTC | iShares Russell 1000 ETF Experiences Big Inflow | ABBV | https://www.nasdaq.com/articles/ishares-russell-1000-etf-experiences-big-inflow | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $255.9 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 119,900,000 to 1... | Among the largest underlying components of IWB, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.2%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of IWB, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.2%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one year price perfor... | Among the largest underlying components of IWB, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, ... | Among the largest underlying components of IWB, in trading today Coca-Cola Co (Symbol: KO) is up about 0.6%, AbbVie Inc (Symbol: ABBV) is up about 0.6%, and Merck & Co Inc (Symbol: MRK) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, ... |
23,772 | 2021-12-06 00:00:00 UTC | 5 Biotech Stocks To Watch In The Stock Market Today | ABBV | https://www.nasdaq.com/articles/5-biotech-stocks-to-watch-in-the-stock-market-today | null | null | Are These Top Biotech Stocks On Your December 2021 Watchlist?
With the start of the new trading week, investors are likely tuning in to the latest updates on the Omicron Covid variant. Accordingly, said investors could also be eyeing the top biotech stocks in thestock market todaystrong> as well. After all, the industr... | Namely, AbbVie revealed that its Crohn’s disease drug candidate, Upadacitinib, met its primary and key secondary endpoints in a Phase 3 induction study. Top Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Moderna Inc. (NASDAQ: MRNA) Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) AbbVie Inc. (NYSE: ABBV) AstraZ... | Top Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Moderna Inc. (NASDAQ: MRNA) Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) AbbVie Inc. (NYSE: ABBV) AstraZeneca (NASDAQ: AZN) Pfizer Inc. Pfizer is a biopharmaceutical company that has improved the lives of millions all over the world. AbbVie Inc. Following t... | Top Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Moderna Inc. (NASDAQ: MRNA) Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) AbbVie Inc. (NYSE: ABBV) AstraZeneca (NASDAQ: AZN) Pfizer Inc. Pfizer is a biopharmaceutical company that has improved the lives of millions all over the world. AbbVie Inc. Following t... | Top Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Moderna Inc. (NASDAQ: MRNA) Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) AbbVie Inc. (NYSE: ABBV) AstraZeneca (NASDAQ: AZN) Pfizer Inc. Pfizer is a biopharmaceutical company that has improved the lives of millions all over the world. AbbVie Inc. Following t... |
23,773 | 2021-12-06 00:00:00 UTC | Biohaven's migraine therapy shows rapid pain relief in late-stage study | ABBV | https://www.nasdaq.com/articles/biohavens-migraine-therapy-shows-rapid-pain-relief-in-late-stage-study | null | null | Dec 6 (Reuters) - Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray for migraine met the main goals in the drugmaker's late-stage study, showing rapid pain relief.
The study, involving 1,405 adults, demonstrated that the drug, zavegepant, was superior to placebo in relieving pain and most other "bother... | Other drugs for treatment include AbbVie's ABBV.N Ubrelvy and Impel NeuroPharma's IMPL.O recently approved intranasal spray, Trudhesa. Dec 6 (Reuters) - Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray for migraine met the main goals in the drugmaker's late-stage study, showing rapid pain relief. The ... | Other drugs for treatment include AbbVie's ABBV.N Ubrelvy and Impel NeuroPharma's IMPL.O recently approved intranasal spray, Trudhesa. Biohaven's Nurtec ODT, has already been approved for the treatment and prevention of migraine in the United States. Pfizer Inc PFE.N would acquire overseas marketing rights to zavegepan... | Other drugs for treatment include AbbVie's ABBV.N Ubrelvy and Impel NeuroPharma's IMPL.O recently approved intranasal spray, Trudhesa. Dec 6 (Reuters) - Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray for migraine met the main goals in the drugmaker's late-stage study, showing rapid pain relief. The ... | Other drugs for treatment include AbbVie's ABBV.N Ubrelvy and Impel NeuroPharma's IMPL.O recently approved intranasal spray, Trudhesa. Dec 6 (Reuters) - Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray for migraine met the main goals in the drugmaker's late-stage study, showing rapid pain relief. Bioh... |
23,774 | 2021-12-06 00:00:00 UTC | Biohaven's migraine therapy shows rapid pain relief in late-stage study | ABBV | https://www.nasdaq.com/articles/biohavens-migraine-therapy-shows-rapid-pain-relief-in-late-stage-study-0 | null | null | Adds analyst comment, background
Dec 6 (Reuters) - Drugmaker Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray to treat migraine showed rapid pain relief and met the main goals in a late-stage study.
In the study involving 1,405 adults, a single intranasal dose of the drug, zavegepant, helped relieve p... | It competes in a crowded migraine therapy market, which includes drugs like AbbVie's ABBV.N orally administered Ubrelvy, and Impel NeuroPharma's IMPL.O recently approved nasal spray, Trudhesa. Adds analyst comment, background Dec 6 (Reuters) - Drugmaker Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray... | It competes in a crowded migraine therapy market, which includes drugs like AbbVie's ABBV.N orally administered Ubrelvy, and Impel NeuroPharma's IMPL.O recently approved nasal spray, Trudhesa. In the study involving 1,405 adults, a single intranasal dose of the drug, zavegepant, helped relieve pain as early as 15 minut... | It competes in a crowded migraine therapy market, which includes drugs like AbbVie's ABBV.N orally administered Ubrelvy, and Impel NeuroPharma's IMPL.O recently approved nasal spray, Trudhesa. Adds analyst comment, background Dec 6 (Reuters) - Drugmaker Biohaven Pharmaceutical BHVN.N said on Monday its intranasal spray... | It competes in a crowded migraine therapy market, which includes drugs like AbbVie's ABBV.N orally administered Ubrelvy, and Impel NeuroPharma's IMPL.O recently approved nasal spray, Trudhesa. In the study involving 1,405 adults, a single intranasal dose of the drug, zavegepant, helped relieve pain as early as 15 minut... |
23,775 | 2021-12-06 00:00:00 UTC | AbbVie's Upadacitinib Achieves Primary & Secondary Endpoints In Phase 3 Study On Crohn's Disease | ABBV | https://www.nasdaq.com/articles/abbvies-upadacitinib-achieves-primary-secondary-endpoints-in-phase-3-study-on-crohns | null | null | (RTTNews) - AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12.
The study showed that a significantly higher proportion of upadacitinib-treated patients achie... | (RTTNews) - AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is ... | (RTTNews) - AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is ... | (RTTNews) - AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is ... | (RTTNews) - AbbVie (ABBV) announced positive results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission and endoscopic responsec at week 12. Upadacitinib, a selective and reversible JAK inhibitor discovered and developed by AbbVie, is ... |
23,776 | 2021-12-06 00:00:00 UTC | AbbVie Updates RINVOQ Indications for the Treatment of RA in the U.S. | ABBV | https://www.nasdaq.com/articles/abbvie-updates-rinvoq-indications-for-the-treatment-of-ra-in-the-u.s. | null | null | Biopharmaceutical company AbbVie (ABBV) updated the U.S. Prescribing Information and Medication Guide for RINVOQ (upadacitinib), a selective JAK inhibitor designed to treat adults with moderate to severe rheumatoid arthritis (RA).
Reason for Update
On September 1, 2021, a Drug Safety Communication (DSC) was issued b... | Biopharmaceutical company AbbVie (ABBV) updated the U.S. Prescribing Information and Medication Guide for RINVOQ (upadacitinib), a selective JAK inhibitor designed to treat adults with moderate to severe rheumatoid arthritis (RA). Furthermore, the updated indication will stand as; “RINVOQ is indicated for the treatment... | Biopharmaceutical company AbbVie (ABBV) updated the U.S. Prescribing Information and Medication Guide for RINVOQ (upadacitinib), a selective JAK inhibitor designed to treat adults with moderate to severe rheumatoid arthritis (RA). Furthermore, the updated indication will stand as; “RINVOQ is indicated for the treatment... | Biopharmaceutical company AbbVie (ABBV) updated the U.S. Prescribing Information and Medication Guide for RINVOQ (upadacitinib), a selective JAK inhibitor designed to treat adults with moderate to severe rheumatoid arthritis (RA). Furthermore, the updated indication will stand as; “RINVOQ is indicated for the treatment... | Biopharmaceutical company AbbVie (ABBV) updated the U.S. Prescribing Information and Medication Guide for RINVOQ (upadacitinib), a selective JAK inhibitor designed to treat adults with moderate to severe rheumatoid arthritis (RA). Furthermore, the updated indication will stand as; “RINVOQ is indicated for the treatment... |
23,777 | 2021-12-03 00:00:00 UTC | Noteworthy Friday Option Activity: ABBV, FCX, EXAS | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-abbv-fcx-exas | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 24,189 contracts has been traded thus far today, a contract volume which is representative of approximately 2.4 million underlying shares (given that e... | Especially high volume was seen for the $120 strike call option expiring December 03, 2021, with 2,485 contracts trading so far today, representing approximately 248,500 underlying shares of ABBV. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVi... | Especially high volume was seen for the $120 strike call option expiring December 03, 2021, with 2,485 contracts trading so far today, representing approximately 248,500 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: Freeport... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 24,189 contracts has been traded thus far today, a contract volume which is representative of approximately 2.4 million underlying shares (given that e... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 24,189 contracts has been traded thus far today, a contract volume which is representative of approximately 2.4 million underlying shares (given that e... |
23,778 | 2021-12-02 00:00:00 UTC | January 2022 Options Now Available For AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/january-2022-options-now-available-for-abbvie-abbv | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.
The put cont... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $119.00 strike highlighted in red: Considering the fact that the $119.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $114.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $119.00 strike price has a current bid of $2.16. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new January 2022 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $119.00 strike highlighted in red: Consid... |
23,779 | 2021-12-02 00:00:00 UTC | AbbVie To Present At The Evercore ISI Conference; Webcast At 12:10 PM ET | ABBV | https://www.nasdaq.com/articles/abbvie-to-present-at-the-evercore-isi-conference-webcast-at-12%3A10-pm-et | null | null | (RTTNews) - AbbVie (ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference.
The event is scheduled to begin at 12:10 PM ET on Dec. 2, 2021.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are... | (RTTNews) - AbbVie (ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie (ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie (ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... | (RTTNews) - AbbVie (ABBV) will participate in the 4th Annual Evercore ISI Virtual HealthCONx Conference. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily ref... |
23,780 | 2021-12-02 00:00:00 UTC | What's Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill? | ABBV | https://www.nasdaq.com/articles/whats-next-for-merck-stock-after-fda-advisors-back-its-covid-19-pill | null | null | [Updated: Dec 1, 2021] Merck Covid-19 Pill Update
Just a few days back we discussed that the stock price of Merck (NYSE: MRK) is being weighed down due to concerns around its Covid-19 antiviral pill – Molnupiravir – which has an efficacy of 30% against hospitalization and death in high-risk patients. Yesterday, a panel... | This can largely be attributed to the company’s recently shared data for its Covid-19 antiviral pill – Molnupiravir – which shows lower efficacy of 30% against hospitalization and death in high-risk patients. Given these changes to our revenues and earnings forecast, we have revised our Merck’s Valuation to $98 per sha... | Merck (MRK) Stock Return (Recent) Comparison With Peers Five-Day Return: PFE highest at 6.3%; JNJ lowest at -2.3% Ten-Day Return: PFE highest at 8.6%; BMY lowest at -4.9% Twenty-One Days Return: PFE highest at 25.1%; MRK lowest at -8.5% [Updated: Nov 3, 2021] MRK Stock Update Merck (NYSE: MRK) recently reported its Q3 ... | [Updated: Dec 1, 2021] Merck Covid-19 Pill Update Just a few days back we discussed that the stock price of Merck (NYSE: MRK) is being weighed down due to concerns around its Covid-19 antiviral pill – Molnupiravir – which has an efficacy of 30% against hospitalization and death in high-risk patients. Merck (MRK) Stock ... | Assuming the FDA approves Molnupiravir following the panel’s decision, the antiviral pill may be available in the market later this month. Now, looking at the stock move, MRK is down a large 15% in a month. We expect the company to likely post revenue and earnings below the consensus estimates, as the spread of Covid-1... |
23,781 | 2021-12-01 00:00:00 UTC | 2 Ridiculously Cheap Dividend Stocks To Buy for 2022 | ABBV | https://www.nasdaq.com/articles/2-ridiculously-cheap-dividend-stocks-to-buy-for-2022 | null | null | The S&P 500 had its worst day of the year on Friday, falling 900 points on the news that there could be a new obstacle in the economy's recovery: omicron, the latest COVID-19 variant.
For investors looking to get away from this volatility and find more safety, holding dividend stocks in your portfolio can be an excelle... | Two dividend stocks that pay an above-average yield and are incredibly cheap right now are AbbVie (NYSE: ABBV) and ViacomCBS (NASDAQ: VIAC). AbbVie AbbVie makes for an ideal buy-and-forget investment. While investors may be worried about the company's expiring patent on rheumatoid arthritis drug Humira, AbbVie's manage... | Two dividend stocks that pay an above-average yield and are incredibly cheap right now are AbbVie (NYSE: ABBV) and ViacomCBS (NASDAQ: VIAC). AbbVie AbbVie makes for an ideal buy-and-forget investment. While investors may be worried about the company's expiring patent on rheumatoid arthritis drug Humira, AbbVie's manage... | Two dividend stocks that pay an above-average yield and are incredibly cheap right now are AbbVie (NYSE: ABBV) and ViacomCBS (NASDAQ: VIAC). And with other pharma stocks like Pfizer, Merck, and Amgen trading at forward price-to-earnings (P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look lik... | And with other pharma stocks like Pfizer, Merck, and Amgen trading at forward price-to-earnings (P/E) multiples of more than 12, AbbVie's multiple of nine makes the stock look like a bargain buy. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of th... |
23,782 | 2021-12-01 00:00:00 UTC | 3 Reasons Pfizer Stock Will Crush the Broader Market in 2022 | ABBV | https://www.nasdaq.com/articles/3-reasons-pfizer-stock-will-crush-the-broader-market-in-2022 | null | null | Pfizer (NYSE: PFE) has been the second-best-performing big pharma stock for the whole of 2021. As of the close of November, the shares were up by an astonishing 45.8% year to date, which is only slightly lower than Eli Lilly's industry-leading 47% gain in 2021.
Pfizer's shares have soared this year due to its dominance... | To put this eye-popping revenue figure into perspective, AbbVie's Humira, which was the best-selling pharma product last year, generated $20.4 billion in sales in 2020. Pfizer's shares have soared this year due to its dominance in the COVID-19 vaccine market, as well as its late-stage trial success with the oral antivi... | To put this eye-popping revenue figure into perspective, AbbVie's Humira, which was the best-selling pharma product last year, generated $20.4 billion in sales in 2020. While its vaccine sales should continue to be stellar in 2022, the company will almost certainly get another major boost from its oral coronavirus pill... | To put this eye-popping revenue figure into perspective, AbbVie's Humira, which was the best-selling pharma product last year, generated $20.4 billion in sales in 2020. Pfizer's shares have soared this year due to its dominance in the COVID-19 vaccine market, as well as its late-stage trial success with the oral antivi... | To put this eye-popping revenue figure into perspective, AbbVie's Humira, which was the best-selling pharma product last year, generated $20.4 billion in sales in 2020. COVID product sales will be off the charts in 2022 Comirnaty is slated to haul in no less than $36 billion in sales in 2021. Pfizer, in fact, ought to ... |
23,783 | 2021-12-01 00:00:00 UTC | Is A Rise Imminent For Merck Stock After An 8% Fall In A Month? | ABBV | https://www.nasdaq.com/articles/is-a-rise-imminent-for-merck-stock-after-an-8-fall-in-a-month | null | null | [Updated: Nov 29, 2021] Merck Covid-19 Pill Update
The stock price of Merck (NYSE: MRK) has seen an 8% fall in a month, while it was down nearly 4% on Friday, Nov 26. This can largely be attributed to the company’s recently shared data for its Covid-19 antiviral pill – Molnupiravir – which shows lower efficacy of 30% a... | This can largely be attributed to the company’s recently shared data for its Covid-19 antiviral pill – Molnupiravir – which shows lower efficacy of 30% against hospitalization and death in high-risk patients. Given these changes to our revenues and earnings forecast, we have revised our Merck’s Valuation to $98 per sha... | Merck (MRK) Stock Return (Recent) Comparison With Peers Five-Day Return: PFE highest at 6.3%; JNJ lowest at -2.3% Ten-Day Return: PFE highest at 8.6%; BMY lowest at -4.9% Twenty-One Days Return: PFE highest at 25.1%; MRK lowest at -8.5% [Updated: Nov 3, 2021] MRK Stock Update Merck (NYSE: MRK) recently reported its Q3 ... | Merck (MRK) Stock Return (Recent) Comparison With Peers Five-Day Return: PFE highest at 6.3%; JNJ lowest at -2.3% Ten-Day Return: PFE highest at 8.6%; BMY lowest at -4.9% Twenty-One Days Return: PFE highest at 25.1%; MRK lowest at -8.5% [Updated: Nov 3, 2021] MRK Stock Update Merck (NYSE: MRK) recently reported its Q3 ... | [Updated: Nov 29, 2021] Merck Covid-19 Pill Update The stock price of Merck (NYSE: MRK) has seen an 8% fall in a month, while it was down nearly 4% on Friday, Nov 26. Out of 78 instances in the last ten years that MRK stock saw a twenty-one day fall of 8.5% or more, 45 of them resulted in MRK stock rising over the subs... |
23,784 | 2021-11-23 00:00:00 UTC | U.S. jury says CVS, other pharmacy chains helped fuel opioid epidemic | ABBV | https://www.nasdaq.com/articles/u.s.-jury-says-cvs-other-pharmacy-chains-helped-fuel-opioid-epidemic | null | null | By Nate Raymond
Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N helped fuel an opioid epidemic in two Ohio counties, in the first trial the companies have faced over the U.S. drug crisis.
Jurors in Cleveland... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. By Nate Raymond Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walg... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. By Nate Raymond Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walg... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. By Nate Raymond Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walg... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. Jurors in Cleveland federal court after six days of deliberationsconcluded that actions by the pharmacy chains helped create... |
23,785 | 2021-11-23 00:00:00 UTC | CVS, other pharmacy chains found liable in their first trial over U.S. opioid epidemic | ABBV | https://www.nasdaq.com/articles/cvs-other-pharmacy-chains-found-liable-in-their-first-trial-over-u.s.-opioid-epidemic | null | null | By Nate Raymond
Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walgreens Boots Alliance Inc WBA.O and Walmart Inc WMT.N helped fuel an opioid epidemic in two Ohio counties, in the first trial the companies have faced over the U.S. drug crisis.
Jurors in Cleveland... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. By Nate Raymond Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walg... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. By Nate Raymond Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walg... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. By Nate Raymond Nov 23 (Reuters) - A federal jury on Tuesday found that pharmacy chain operators CVS Health Corp CVS.N, Walg... | Other trials are underway in New York involving drugmakers Teva Pharmaceutical Industries Ltd TEVA.TA and AbbVie Inc ABBV.N, and in Washington state with the three largest U.S. drug distributors. Jurors in Cleveland federal court concluded that actions by the pharmacy chains helped create a public nuisance that resulte... |
23,786 | 2021-11-21 00:00:00 UTC | Should You Buy This Blue Chip Biotech Stock? | ABBV | https://www.nasdaq.com/articles/should-you-buy-this-blue-chip-biotech-stock-2021-11-21 | null | null | This is arguably the most difficult time to be an income investor in decades. For one, the S&P 500 is yielding less than 1.3%, which is very close to its all-time low of 1.1% set back in 2000. Along with this, last month's annual inflation rate of 6.2% set a 31-year high. Anyone sitting on cash and waiting for a market... | The most encouraging takeaway of AbbVie's third-quarter undoubtedly was that its next-gen immunology drugs Skyrizi and Rinvoq saw their combined revenue surge 92.2% to $1.25 billion. This gives income investors a chance to scoop up shares of AbbVie and its well-covered 4.5% yield before the market warms up to the stock... | AbbVie's largest segment, the immunology segment led by Humira, followed by Skyrizi and Rinvoq, contributed to 60.5% of its total revenue growth in the third quarter. Humira's revenue edged 5.6% higher year over year to $5.43 billion in the third quarter, which contributed to nearly one-third (32.2%) of AbbVie's third-... | AbbVie consistently beats expectations When AbbVie reported its third-quarter earnings on Oct. 29, the company managed to top both analysts' revenue and non-GAAP (adjusted) earnings per share (EPS) estimates for the 11th straight quarter. AbbVie's largest segment, the immunology segment led by Humira, followed by Skyri... | Humira's revenue edged 5.6% higher year over year to $5.43 billion in the third quarter, which contributed to nearly one-third (32.2%) of AbbVie's third-quarter immunology segment revenue growth. That's why analysts are forecasting AbbVie will deliver 4.5% annual adjusted EPS growth over the next five years despite Hum... |
23,787 | 2021-11-21 00:00:00 UTC | 4 Top Dividend Stocks I'd Buy If I Were About to Retire | ABBV | https://www.nasdaq.com/articles/4-top-dividend-stocks-id-buy-if-i-were-about-to-retire-2021-11-21 | null | null | There's a different mindset for investing when you're near the point of leaving the workplace. Your focus shifts a lot more toward steady income and less to generating tremendous growth. That means dividend stocks move to the forefront.
My retirement remains years away -- in large part because I enjoy what I do too muc... | However, AbbVie has plenty of other strong products in its lineup, including autoimmune disease drug Skyrizi and the blockbuster Botox franchise picked up with its acquisition of Allergan. AbbVie My fourth pick boasts the most impressive dividend track record of the group. AbbVie (NYSE: ABBV) is a Dividend Aristocrat, ... | See the 10 stocks *Stock Advisor returns as of November 10, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie My fourth pick boasts the most impressive dividend track record of the group. AbbVie (NYSE: ABBV) is a Dividend Arist... | See the 10 stocks *Stock Advisor returns as of November 10, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie My fourth pick boasts the most impressive dividend track record of the group. AbbVie (NYSE: ABBV) is a Dividend Arist... | See the 10 stocks *Stock Advisor returns as of November 10, 2021 Keith Speights owns shares of AbbVie, Brookfield Renewable Corporation Inc., Brookfield Renewable Partners L.P., and Devon Energy. AbbVie My fourth pick boasts the most impressive dividend track record of the group. AbbVie (NYSE: ABBV) is a Dividend Arist... |
23,788 | 2021-11-19 00:00:00 UTC | 7 Dividend Stocks to Buy for 2022 and Hold Forever | ABBV | https://www.nasdaq.com/articles/7-dividend-stocks-to-buy-for-2022-and-hold-forever-2021-11-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Editor’s Note: “7 Dividend Stocks to Buy for 2022 and Hold Forever” was originally published in October 2021. It has been updated to include the latest available information.
The allure of dividend stocks should be increasing right now. The Fed has signaled... | 6 Mega-Cap Stocks That Make Great Stocking Stuffers As an example, AbbVie (NYSE:ABBV) carries a beta, which measures volatility, of 0.80. According to the alliance of oil-exporting nations: “World oil demand will plateau in the late 2030s and could by then have begun to decline, OPEC said on Thursday, in a major shift ... | 6 Mega-Cap Stocks That Make Great Stocking Stuffers As an example, AbbVie (NYSE:ABBV) carries a beta, which measures volatility, of 0.80. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s Note: “7 Dividend Stocks to Buy for 2022 and Hold Forever” was originally published in October 2021. That’s pr... | 6 Mega-Cap Stocks That Make Great Stocking Stuffers As an example, AbbVie (NYSE:ABBV) carries a beta, which measures volatility, of 0.80. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s Note: “7 Dividend Stocks to Buy for 2022 and Hold Forever” was originally published in October 2021. That’s pr... | 6 Mega-Cap Stocks That Make Great Stocking Stuffers As an example, AbbVie (NYSE:ABBV) carries a beta, which measures volatility, of 0.80. The company hasn’t reduced that dividend since 1984. The upside underpinning LMT stock exists in the average target stock price of $378 a modest increase from today’s price of around... |
23,789 | 2021-11-18 00:00:00 UTC | 5 Biotech Stocks To Check Out In The Stock Market Now | ABBV | https://www.nasdaq.com/articles/5-biotech-stocks-to-check-out-in-the-stock-market-now | null | null | 5 Top Biotech Stocks For Your November 2021 Watchlist
While investors digest the latest round of earnings and data concerning retail spending, the biotech industry remains hard at work. Accordingly, biotech stocks could also be in focus in the stock market because of this. Ever since the onslaught of the coronavirus pa... | Best Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) Inovio Pharmaceuticals Inc. (NASDAQ: INO) AbbVie Inc. (NYSE: ABBV) Sanofi SA (NASDAQ: SNY) Pfizer Inc. First up, we have Pfizer, a biopharmaceutical company that has developed many life-changing drugs and therapies for millions a... | Best Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) Inovio Pharmaceuticals Inc. (NASDAQ: INO) AbbVie Inc. (NYSE: ABBV) Sanofi SA (NASDAQ: SNY) Pfizer Inc. First up, we have Pfizer, a biopharmaceutical company that has developed many life-changing drugs and therapies for millions a... | Best Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) Inovio Pharmaceuticals Inc. (NASDAQ: INO) AbbVie Inc. (NYSE: ABBV) Sanofi SA (NASDAQ: SNY) Pfizer Inc. First up, we have Pfizer, a biopharmaceutical company that has developed many life-changing drugs and therapies for millions a... | Best Biotech Stocks To Watch Right Now Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) Inovio Pharmaceuticals Inc. (NASDAQ: INO) AbbVie Inc. (NYSE: ABBV) Sanofi SA (NASDAQ: SNY) Pfizer Inc. First up, we have Pfizer, a biopharmaceutical company that has developed many life-changing drugs and therapies for millions a... |
23,790 | 2021-11-18 00:00:00 UTC | AbbVie Brings VENCLEXTA Plus Obinutuzumab To Chronic Lymphocytic Leukemia Patients In Quebec | ABBV | https://www.nasdaq.com/articles/abbvie-brings-venclexta-plus-obinutuzumab-to-chronic-lymphocytic-leukemia-patients-in | null | null | (RTTNews) - AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. Following the agreement, Quebec is the first province to reimburse the combination t... | (RTTNews) - AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. VENCLEXTA is jointly commercialized by AbbVie and Genentech in the U.S. and by AbbVi... | (RTTNews) - AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. VENCLEXTA is jointly commercialized by AbbVie and Genentech in the U.S. and by AbbVi... | (RTTNews) - AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. VENCLEXTA is jointly commercialized by AbbVie and Genentech in the U.S. and by AbbVi... | (RTTNews) - AbbVie (ABBV) has reached an agreement with the pan-Canadian Pharmaceutical Alliance for VENCLEXTA in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia. VENCLEXTA is jointly commercialized by AbbVie and Genentech in the U.S. and by AbbVi... |
23,791 | 2021-11-18 00:00:00 UTC | AbbVie’s Gets EC Approval for SKYRIZI | ABBV | https://www.nasdaq.com/articles/abbvies-gets-ec-approval-for-skyrizi | null | null | AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) for the treatment of active psoriatic arthritis in adults. These patients include individuals who have had an inadequate response or have been i... | AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) for the treatment of active psoriatic arthritis in adults. See Top Smart Score Stocks on TipRanks >> Official Comments The VC of AbbVie, Michael... | AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) for the treatment of active psoriatic arthritis in adults. The average AbbVie price target of $129.30 implies 10.2% upside potential from curren... | AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) for the treatment of active psoriatic arthritis in adults. See Top Smart Score Stocks on TipRanks >> Official Comments The VC of AbbVie, Michael... | (See AbbVie stock charts on TipRanks) Wall Street’s Take On November 17, Truist Financial analyst Robyn Karnauskas reiterated a Buy rating on the stock with a price target of $118. AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used s... |
23,792 | 2021-11-17 00:00:00 UTC | AbbVie: SKYRIZI Gets EU Approval To Treat Adults With Active Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-skyrizi-gets-eu-approval-to-treat-adults-with-active-psoriatic-arthritis-0 | null | null | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis.
Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with ... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with ... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. The EC approval was based on data from two Phase 3 studies evaluating SKYRIZI in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2. The... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. The EC approval was based on data from two Phase 3 studies evaluating SKYRIZI in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2. The... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with ... |
23,793 | 2021-11-17 00:00:00 UTC | 1 Dividend Stock to Help You Fight Inflation | ABBV | https://www.nasdaq.com/articles/1-dividend-stock-to-help-you-fight-inflation | null | null | Inflation is a problem in the U.S. The Consumer Price Index, a measure of the change in prices for some common goods and services, rose by 6.2% in the 12-month period ending Oct. 31. That's well above the U.S. Federal Reserve's long-term inflation target of 2%. Inflation chips away at our purchasing power, and that's w... | And given AbbVie's rich pipeline -- with 21 phase 3 studies and many more early-stage clinical trials -- the company is well-positioned to add more products to replace Humira. AbbVie is here to stay An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding divid... | There are plenty of excellent dividend stocks on the market; one great option to consider is pharma giant AbbVie (NYSE: ABBV). ABBV data by YCharts. Looking at AbbVie's dividend record AbbVie made its debut on the stock market in January 2013 when it split from its former parent company, Abbott Laboratories. | Looking at AbbVie's dividend record AbbVie made its debut on the stock market in January 2013 when it split from its former parent company, Abbott Laboratories. AbbVie is here to stay An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding dividend-paying stoc... | There are plenty of excellent dividend stocks on the market; one great option to consider is pharma giant AbbVie (NYSE: ABBV). ABBV data by YCharts. Looking at AbbVie's dividend record AbbVie made its debut on the stock market in January 2013 when it split from its former parent company, Abbott Laboratories. |
23,794 | 2021-11-17 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABBV, NVAX, ADBE | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-abbv-nvax-adbe | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 44,333 contracts have traded so far, representing approximately 4.4 million underlying shares. That amounts to about 77.8% of ABBV's average daily trading volume over ... | Particularly high volume was seen for the $120 strike call option expiring December 17, 2021, with 11,115 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie ... | Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: Novavax, Inc. (Symbol: NVAX) saw options trading volume of 48,489 contracts, representing approximately 4.8 million underlying shares or approximately 76.5% of NVAX's average daily trading volume over the ... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 44,333 contracts have traded so far, representing approximately 4.4 million underlying shares. Particularly high volume was seen for the $120 strike call option expiri... | Particularly high volume was seen for the $120 strike call option expiring December 17, 2021, with 11,115 contracts trading so far today, representing approximately 1.1 million underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: N... |
23,795 | 2021-11-17 00:00:00 UTC | AbbVie: SKYRIZI Gets EU Approval To Treat Adults With Active Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-skyrizi-gets-eu-approval-to-treat-adults-with-active-psoriatic-arthritis | null | null | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis.
Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with ... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with ... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. The EC approval was based on data from two Phase 3 studies evaluating SKYRIZI in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2. The... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. The EC approval was based on data from two Phase 3 studies evaluating SKYRIZI in psoriatic arthritis patients, KEEPsAKE-1 and KEEPsAKE-2. The... | (RTTNews) - AbbVie (ABBV) announced that the European Union's European Commission has approved SKYRIZI (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with ... |
23,796 | 2021-11-17 00:00:00 UTC | Will Investors Win With Johnson & Johnson's Planned Spinoff? Here's What History Shows | ABBV | https://www.nasdaq.com/articles/will-investors-win-with-johnson-johnsons-planned-spinoff-heres-what-history-shows | null | null | The biggest healthcare company in the world is preparing to shrink. Johnson & Johnson (NYSE: JNJ) announced last week that it plans to spin off its consumer healthcare business into a separate publicly traded entity.
J&J said that this move will unlock shareholder value and accelerate growth. But will investors really ... | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years. | In 2013, Abbott (NYSE: ABT) created AbbVie (NYSE: ABBV). AbbVie took the innovative pharmaceuticals business, with autoimmune disease drug Humira as its primary star. Both Abbott and AbbVie went on to achieve solid success, performing much better than Abbott had in the previous years. |
23,797 | 2021-11-16 00:00:00 UTC | Report says drugmakers impose unjustified U.S. price increases; spending on AbbVie drug rises $1.4 billion | ABBV | https://www.nasdaq.com/articles/report-says-drugmakers-impose-unjustified-u.s.-price-increases-spending-on-abbvie-drug | null | null | By Ahmed Aboulenein
WASHINGTON, Nov 16 (Reuters) - Drugmakers hiked U.S. prices on seven of the 10 costliest prescription drugs in 2020 without justification, increasing drug spending by $1.67 billion, a U.S. group that reviews the value of medicines said on Tuesday.
AbbVie Inc's ABBV.N widely used Humira rheumatoid ar... | AbbVie Inc's ABBV.N widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending. AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value a... | AbbVie Inc's ABBV.N widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending. AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value a... | AbbVie Inc's ABBV.N widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending. AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value a... | AbbVie Inc's ABBV.N widely used Humira rheumatoid arthritis drug accounted for the majority of the spending increase, with a net price increase of 9.6% leading to an almost $1.4 billion increase in U.S. spending. AbbVie said in a response to ICER that the report lacked context because ICER does not perform full value a... |
23,798 | 2021-11-16 00:00:00 UTC | Merck Is a Dividend Play Ready to Get Back in Gear | ABBV | https://www.nasdaq.com/articles/merck-is-a-dividend-play-ready-to-get-back-in-gear | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Before the COVID-19 pandemic, Merck (NYSE:MRK) stock was a good one to own. The performance of Merck stock matched that of the S&P 500, and it paid a steadily rising dividend.
MRK) logo outside of corporate building" width="300" height="169">
Source: Atmosp... | It should become the world’s best-selling drug next year, as Abbvie (NYSE:ABBV) gets set to lose U.S. exclusivity for its Humira in 2023. The Good News Merck’s molnupiravir, an antiviral pill for people with mild Covid-19 at risk for more serious illness, was approved recently by U.K. regulators. 7 Semiconductor Stocks... | It should become the world’s best-selling drug next year, as Abbvie (NYSE:ABBV) gets set to lose U.S. exclusivity for its Humira in 2023. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Before the COVID-19 pandemic, Merck (NYSE:MRK) stock was a good one to own. The Good News Merck’s molnupiravir, an anti... | It should become the world’s best-selling drug next year, as Abbvie (NYSE:ABBV) gets set to lose U.S. exclusivity for its Humira in 2023. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Before the COVID-19 pandemic, Merck (NYSE:MRK) stock was a good one to own. 7 Semiconductor Stocks to Buy for the Holid... | It should become the world’s best-selling drug next year, as Abbvie (NYSE:ABBV) gets set to lose U.S. exclusivity for its Humira in 2023. The Good News Merck’s molnupiravir, an antiviral pill for people with mild Covid-19 at risk for more serious illness, was approved recently by U.K. regulators. Even the big molnupira... |
23,799 | 2021-11-15 00:00:00 UTC | Buffett's Berkshire cuts U.S. drugmaker stakes, invests in drug royalty company | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-cuts-u.s.-drugmaker-stakes-invests-in-drug-royalty-company-2021-11-15 | null | null | By Jonathan Stempel
Nov 15 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it eliminated its investment in Merck & Co MRK.N and reduced its stakes in AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N, as it pared its overall stock market investments.
Berkshire also eliminated its small stake... | Its larger revenue streams come from Vertex Pharmaceuticals Inc VRTX.O treatments for cystic fibrosis, Biogen Inc's BIIB.O Tysabri for multiple sclerosis, and AbbVie's Imbruvica for various cancers. By Jonathan Stempel Nov 15 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it eliminated its in... | By Jonathan Stempel Nov 15 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it eliminated its investment in Merck & Co MRK.N and reduced its stakes in AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N, as it pared its overall stock market investments. Berkshire's respective share stakes in Ab... | By Jonathan Stempel Nov 15 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it eliminated its investment in Merck & Co MRK.N and reduced its stakes in AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N, as it pared its overall stock market investments. Berkshire's respective share stakes in Ab... | By Jonathan Stempel Nov 15 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it eliminated its investment in Merck & Co MRK.N and reduced its stakes in AbbVie Inc ABBV.N and Bristol-Myers Squibb Co BMY.N, as it pared its overall stock market investments. Berkshire's respective share stakes in Ab... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.